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ABSTRACT
DEVELOPING INJECTABLE AND IMPLANTABLE POLYMER ZWITTERION
PLATFORMS FOR GLIOBLASTOMA TREATMENT
FEBRUARY 2022
SARAH M. WARD, B.S., TEXAS A&M UNIVERSITY
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Todd Emrick

This dissertation describes the synthesis, characterization, and application of novel
polymer zwitterion-drug conjugates intended for treating glioblastoma, with a particular
focus on phosphorylcholine (PC) and temozolomide (TMZ). Using versatile TMZcontaining monomers, injectable polymer prodrugs and implantable polymeric hydrogels
were prepared over a broad range of drug incorporations with tunable properties, making
them ideally suited for further in vivo and clinical evaluations. The work presented here
greatly expands the knowledge base of TMZ formulations and gives rise to several routes
which circumvent the challenges associated with its use.
Chapter 2 describes the incorporation of a novel TMZ-methacrylate monomer into
random and block copolymers by controlled free radical polymerizations. The solution
properties of these polyMPC-TMZ copolymers was investigated, and it was demonstrated
that TMZ conjugation to the polymer backbone significantly enhanced drug stability in
physiological conditions. The antitumor activity of polyMPC-TMZ copolymers was
demonstrated in chemosensitive (U87MG) and chemoresistant (T98G) human
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glioblastoma cell lines. Additionally, the impact of a redox-responsive drug-to-polymer
linker on drug release and cytotoxicity was investigated.
Chapter 3 augments the polyMPC-TMZ conjugate platform through the
incorporation of additional co-monomers, including disulfiram (DSF) and gemcitabine
(GEM), to overcome chemoresistance in glioblastoma cells. These polymers—envisioned
as staggered release materials—employ various methods of covalent conjugation
chemistries and demonstrated drug release and stability properties dependent on the pH
and reducing potential of the buffer environment.
Finally, Chapter 4 details the preparation of polymeric hydrogels based on MPC,
poly(ethylene glycol) (PEG), and the polyMPC-TMZ conjugates described in Chapter 2.
Physical encapsulation of the prodrugs into UV-crosslinked hydrogels gave rise to pellets
with tunable drug release, enhanced shelf-stability in ambient conditions, and robust
swelling and mechanical properties. Additionally, preliminary examinations of these
pellets in healthy (HEK293A) and glioblastoma (U87MG) cell lines were conducted,
providing insight for the development of additional routes of hydrogel preparation and drug
incorporation.
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CHAPTER 1
POLYMERS IN THERAPEUTICS: MACROMOLECULAR DESIGN AND
STRATEGIES FOR GLIOBLASTOMA

1.1 Introduction
Synthetic polymers are now utilized across a range of consumer materials and
advanced technologies. In particular, hydrophilic polymers have transformed medicine by
their many useful attributes, including their nanoscale size, synthetic versatility, and
biocompatibility. Today, a variety of hydrophilic polymers are used as surface coatings,
sensors, and drug delivery systems. For drug delivery platforms, synthetic polymers confer
critical advantages to both small molecule drug and protein therapeutics.1,2 Small molecule
chemotherapeutics are limited by rapid clearance following administration and off-target
toxicity arising from non-specific tissue accumulation. While recurring dosing schedules
may allow for consistent drug concentrations to overcome the former issue, these may
result in increased off-target toxicity and moderate-to-severe side effects which threaten
patient health and safety.3–5 Additionally, many prescribed chemotherapeutics are
hydrophobic, reducing the bioavailability of the drug. Conventional drug delivery vehicles
(i.e., excipients including non-ionic surfactants and cyclodextrins) are often similarly
associated with off-target toxicity.6,7
By contrast, the large size of polymers makes them ideally suited as vehicles for
drug transport and delivery. Covalent conjugation greatly increases the hydrodynamic size
of the system well beyond that of the free therapeutic, allowing for slower renal clearance
and selective tumor targeting through the enhanced permeability and retention (EPR)
effect.1,2,8,9 Additionally, selection of hydrophilic or amphiphilic polymers imparts
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enhanced solubility to hydrophobic drugs and provides a sheltered environment which
minimizes degradation.10–13 The synthetic versatility of polymers allows for the
incorporation of functional groups which may be utilized in post-polymerization
conjugation strategies to impart targeting moieties or therapeutics as pendent or chain-end
groups. Such chemical functionality also allows for covalent or physical crosslinking of
hydrophilic monomers and polymers into hydrogels and other soft materials. Such threedimensional structures may physically or covalently encapsulate therapeutic materials,
such as small molecule drugs or proteins, and serve as platforms for cell adhesion and
growth.14–16 Moreover, the incorporation of stimuli-responsive moieties into the hydrogel
structures allows for tailored release of therapeutics or degradation of the matrices into
biocompatible materials.

1.2 PEGylated Therapeutics
Poly(ethylene glycol) (PEG), or poly(ethylene oxide) (PEO), has seen extensive
use in polymer therapeutics due to its water solubility and relative bio-inertness. The
attachment of PEG to therapeutic materials either covalently or non-covalently (i.e.,
PEGylation) yields materials which exhibit slower in vivo clearance and often enhanced
therapeutic efficacy relative to the free therapeutic.8 PEGylation is typically performed
through coupling of a reactive chain end of PEG to a functional handle of a therapeutic a
small-molecule drug or protein (Figure 1.1A). Chemistries utilizing PEG-aldehydes, PEGmaleimides, and PEG-thiols have been widely explored, with high yields, easily removable
by-products, and mild reaction conditions.17,18 However, compared to other polymeric
materials, PEG is limited by its functionality: strategies for the covalent attachment of
therapeutics are limited to the polymer chain-ends. Linear PEG has a maximum of two
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hydroxyl end groups for conjugation, while multi-arm PEG reagents typically have up to
four hydroxyl end groups (Figure 1.1A). As such, PEGylated therapeutics which exhibit
high water solubility (i.e., high PEG molecular weight) are associated with low weight
percent incorporations of drug in the conjugated structure. Additionally, PEG has been
demonstrated to “salt out” of aqueous solutions, particularly at higher temperatures, as the
ethylene oxide units are dehydrated by hydrated ions, thereby reducing its solubility and
bioavailability.19,20
(A)
linear PEG

multi-arm PEG

(B)

Adagen®
Movantik®

Figure 1.1: Examples of PEG reagents and functional groups (R) for small molecule drug
and protein conjugation. (B) Examples of FDA-approved PEGylated therapeutics
Adagen® and Movantik®.

Nevertheless, PEGylated therapeutics remain prominent in new literature and
clinical studies, with over 20 PEGylated therapeutics gaining approval by the U.S. Food
and Drug Administration (FDA). Notably, while most of these therapeutics are proteinbased (e.g., Adagen®, Asparlas®, and Neulasta®), there are some examples of PEGylated
small molecules (e.g, Movantik®), as shown in Figure 1.2B.21,22
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While PEG is widely considered to be non-immunogenic, there have been reports
on PEG antibody (anti-PEG immunoglobin M (IgM)) production in animal models and
patients systemically treated with PEGylated materials.23–25 Anti-PEG IgM was first
reported in vivo in 1983 by Richter and Akerblom, in a rabbit model which demonstrated
an immune response following administration of PEGylated ovalbumin (OVA).26 In recent
years, there have been numerous such reports on the production of anti-PEG IgM,
particularly following the second administration of PEGylated nanoparticles (NPs),
micelles, liposomes, and solubilized therapeutics. This immune response gives rise to the
accelerated blood clearance (ABC) phenomenon: following production of anti-PEG IgM,
PEGylated agents are recognized by the immune system (i.e., mononuclear phagocyte
system) and then rapidly cleared from circulation, leading to an overall decreased
therapeutic efficacy.25 Moreover, upon antibody induction, the passive drug targeted
afforded by PEGylation and the EPR effect is lost, leading to an increase in negative side
effects such as off-target organ accumulation. Concerningly, anti-PEG IgM production is
not necessarily linked to PEGylated therapeutic administration, as pre-existing anti-PEG
antibodies have been detected in the plasma of up to 22-25% of normal donors.27,28
Despite these demonstrations of PEG immunogenicity, further studies are needed
to understand the influence of PEG architecture, molecular weight, and conjugation
strategies (as well as patient genetic factors) on the production of anti-PEG antibodies. The
most widely utilized assay for detecting anti-PEG IgM—enzyme-linked immunosorbent
assay, or ELISA—is not consistently applied by researchers, which suggests that anti-PEG
antibody production may be estimated incorrectly in many cases.24 Additionally, many
chemotherapeutics suppress immunogenic responses, such that PEG immunogenicity
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concerns may not be relevant in anti-cancer treatments.29 Nevertheless, the development
of PEG alternatives which are safe and non-immunogenic remains a promising pathway
forward for therapeutics.

1.3 Polymer Zwitterions
Polymer zwitterions are promising alternatives to conventional PEG-based
therapeutics. They are composed of covalently bound cation-anion pairs (i.e., zwitterions),
which can be incorporated as moieties within polymer backbones or, more commonly, as
pendent groups (Figure 1.2A). The presence of charges within the structure of polymer
zwitterions gives them high water solubility, and their overall charge-neutral nature leads
to excellent non-fouling characteristics against bacteria and proteins.10,11,30,31
(A)

(B)

phosphorylcholine (PC)

synthetic polymer zwitterions

ubiquitous in nature

charge-neutral, biocompatible,
water-soluble

polySBMA

polyCBMA

polyMPC

polyMCP
‘reverse zwitterion’

R=

Figure 1.2: (A) Translation of zwitterions (e.g., phosphorylcholine) found in nature to
synthetic polymer platforms with zwitterions incorporated as backbone or pendent groups.
(B) Chemical structures of common polymer zwitterions.
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As such, polymer zwitterions have been extensively utilized in a variety of
applications, including as surfactants and detergents, biocompatible surfaces, antifouling
coatings, and vehicles for drug delivery.10,11 Common synthetic polymer zwitterions are
based on phosphorylcholine (PC), sulfobetaine (SB), and carboxybetaine (CB) structures
(Figure 1.2B). Of these, polymers incorporating PC moieties—specifically through the
polymerization of 2-methacryloyloxyethyl phosphorylcholine (MPC)—are especially
attractive for biomedical applications. The PC groups of polyMPC are found in the polar
head group of mammalian cell membrane phospholipids,32 which may reduce or
completely suppress unwanted immunogenic responses. Moreover, polyMPC has
demonstrated high water solubility (>100 mg/mL) in pure water and over a range of salt
concentrations and temperatures. This water solubility is retained even upon covalent
conjugation of highly hydrophobic drugs.10 Inverting the PC zwitterion structure to yield
“reverse zwitterions” of choline phosphate (CP) opens additional opportunities to directly
incorporate functional handles into the zwitterionic structure for drug conjugation and
crosslinking chemistries.33,34
Many polymer zwitterions are readily prepared by conventional free radical
polymerizations, as well as controlled free radical polymerization techniques (e.g., atom
transfer radical polymerization (ATRP) or reversible addition-fragmentation chain transfer
(RAFT)), which produce well-defined polymer structures with narrow molecular weight
distributions and active chain ends.10,11,35 Polymers synthesized by ATRP or RAFT may
be chain-extended through additional controlled polymerizations with co-monomers that
yield materials with tunable amphiphilicity, architecture (i.e., block copolymers), and
solvent-induced assembly.
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Critical to this thesis is the use of RAFT polymerization to prepare polymer
zwitterions for biomedical applications. RAFT conditions are metal-free, suitable for the
polymerization of many monomer types (e.g., acrylates, methacrylates, and styrenic
derivatives), and tolerant of functional group, allowing for the preparation of polymers with
a range of reactive groups to be employed in post-polymerization conjugation and
crosslinking. This polymerization methodology hinges on the use of chain-transfer agents
(CTAs)—typically thiocarbonylthio compound, such as dithioesters, trithiocarbonates, and
dithiocarbamates (Figure 1.3A)—which reversibly transfer the active radical species and
establishes an equilibrium between active and dormant polymer chains (Figure 1.3B).
(A)

dithiobenzoates

(B)

trithiocarbonates

dithiocarbamates

Initiation:

Reversible Chain-Transfer/Propagation:

active
chain

dormant
chain

Re-Initiation:

Figure 1.3: (A) Representative structures of chain-transfer agent (CTA) compounds. (B)
Mechanism for the RAFT polymerization of vinyl monomers.
1.4 Glioblastoma as the Therapeutic Target for Polymer Zwitterions
Glioblastoma represents the most commonly diagnosed central nervous system
(CNS) tumor in the United States.36 Its highly aggressive and infiltrative nature requires a
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strict regimen of treatment involving a combination of surgical resection of the tumor,
radiotherapy, and chemotherapy. However, even with early diagnosis and rapid treatment,
the average survival time of glioblastoma patients following diagnosis remains low at 1215 months.37,38 Moreover, tumor recurrence is inevitable for most patients, with growth
typically occurring within 2 cm of the original tumor site.39–41 Due to the heterogenous
nature of the tumor mass and the infiltrative nature of glioblastoma cells, chemotherapy
remains a critical component of treatment. Small, lipophilic alkylating agents—including
carmustine, lomustine, and procarbazine—have proven efficacious against glioblastoma
and are among the few chemotherapeutics capable of traversing the blood-brain barrier
(BBB). The current first-line chemotherapeutic for glioblastoma treatment is orally or
intravenously administered temozolomide (TMZ), sold under the brand name Temodar.
TMZ is a prodrug which readily degrades in physiological conditions to release a
methyldiazonium cation, which then preferentially methylates guanine residues at the O6
position and leads to DNA mismatch and eventual cell death (Figure 1.4).42,43 While
protracted dosing schedules can improve tumor response even in enzyme-mediated
resistant tumors,3–5 the efficacy of TMZ remained limited by poor pharmacokinetics (i.e.,
rapid renal clearance and low bioavailability) and off-target toxicity.
Compared to more conventional chemotherapeutics that are used clinically today,
such as doxorubicin, TMZ presents several unique challenges in its use. Its hydrolytic
instability leads to rapid degradation, with a reported half-life (t1/2) of only 1 h in pH 7.4
phosphate-buffered saline (PBS) at 37 °C and 1.8 h in blood plasma, necessitating frequent
dosing schedules clinically.13,42–45 Moreover, this decomposition has resulted in
inconsistent descriptions in the literature on the viabilities of TMZ and TMZ-loaded
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DNA alkylation of
guanine residues

Figure 1.4: Degradation of temozolomide (TMZ) at physiological pH, affording 5-(3methyltriazen-1-yl)imidazole-4-carboxamide (MTIC), followed by acid-catalyzed
degradation yielding 5-aminoimidazole-4-carboxamide (AIC) and the methyldiazonium
cation. The cation alkylates DNA (shown here at the O6 position of guanine) and leads to
DNA mismatch and cell death.
materials, both in animals and human glioblastoma cell lines. For example, the halfmaximal inhibitory concentration (IC50) values of native TMZ in two human-derived cell
lines—U87MG (chemosensitive) and T98G (chemoresistant)—are reported over broad
ranges from 10-500 μM and 250-1600 μM, respectively.46 Such variability suggests that
experimental error (e.g., prematurely dissolving TMZ into media before testing, resulting
in degradation prior to conducting a cell cultured experiment) is one of the key challenges
of TMZ-based systems. Synthetic approaches to incorporating TMZ into small molecule
and polymeric platforms, made possible by the drug’s amide group, are additionally
inhibited by this instability, as both conjugation chemistries and purification procedures
must be carefully optimized to prevent unwanted degradation. Beyond covalent methods,
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its inherent hydrophobicity similarly restricts methods of incorporation into the watersoluble materials necessary for biomedical applications.

1.5 Thesis Outline
This thesis describes the synthesis, characterization, and evaluation of a novel
library of polymer zwitterion-based systems for chemotherapeutic materials, with a
particular focus on drugs associated with glioblastoma treatment. While temozolomide
(TMZ) remains the first-line chemotherapeutic for glioblastoma patients, the many
challenges associated with its use require innovative strategies which can be addressed by
polymeric materials. As such, this thesis seeks to develop novel pathways to injectable and
implantable TMZ-loaded materials through controlled free radical polymerization
techniques (i.e., RAFT), post-polymerization conjugation strategies, and the photoinitiated
crosslinking of hydrogel matrices.
Chapter 2 describes the synthesis, characterization, and application of polymer
prodrugs incorporating the glioblastoma drug TMZ as pendent groups. Using a versatile
TMZ-methacrylate monomer, random and block copolymers were synthesized by RAFT
polymerizations with MPC or by chain-extension from a polyMPC macro-CTA (ACS
Macro Letters 2017; Molecular Pharmaceutics 2018). The well-defined and water-soluble
polyMPC-TMZ copolymers resulting from these syntheses were isolated with TMZ
incorporations of up to 50 mole %. TMZ stability was evaluated in physiological
conditions, demonstrating an architecture-dependent effect. Moreover, the aqueous
assembly characteristics of the polymer conjugates were evaluated by dynamic light
scattering (DLS) and transmission electron microscopy (TEM), and the cytotoxicity of
polyMPC-TMZ copolymers was demonstrated in both chemosensitive and chemoresistant
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human glioblastoma cell lines. A preliminary expansion of this polyMPC-TMZ platform
was demonstrated with redox-responsive conjugates which utilized disulfides as the
polymer-to-drug linker.
Chapter 3 details an expansion of the polyMPC-TMZ platform to include multiple
pendent chemotherapeutics that employ various methods of conjugation chemistries the
drug and polymer backbone. While methods of addressing the enzyme-mediated
chemoresistance of glioblastoma cells to TMZ were generally unsuccessful, new routes to
accessing disulfide-containing polyMPC-TMZ conjugates were explored. These
polymers—visualized as staggered release materials—demonstrated hydrolytic stabilities
and drug release properties that were dependent on pH and the presence of a reducing
environment.
Finally, Chapter 4 describes the preparation of polymer hydrogels based on MPC,
PEG, and the polyMPC-TMZ conjugates described previously. PolyMPC-TMZ
copolymers with random and block architectures were physically encapsulated into PCPEG hydrogel pellets fabricated by UV irradiation in 24- and 96-well cell plates. These
hydrogel wafers demonstrated tunable drug release in both acidic and neutral conditions,
even after several months of storage under ambient conditions, with consistent and robust
swelling properties. The mechanical properties of the hydrogels, evaluated by rheology and
dynamic mechanical analysis (DMA), were found to be on the order of brain tissue.
Furthermore, preliminary examinations of the biocompatibility of the hydrogel
components and gels with and without loaded drug were performed in healthy and
cancerous human cell lines. Additional routes to drug-loaded hydrogels which address
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concerns raised by the cell viability studies are presented and demonstrate the versatility
of this polymer hydrogel platform.
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CHAPTER 2
POLYMER-TEMOZOLOMIDE CONJUGATES FOR TREATING
GLIOBLASTOMA

2.1 Introduction
Glioblastoma is a solid neoplasm which originates from non-neuronal glial cells of
the brain and represents the most commonly diagnosed central nervous system tumor in
the United States.1 Due to its highly aggressive and lethal nature, glioblastoma is treated
clinically using a regimen of surgery, radiation, and chemotherapy.2,3

Despite the

demonstrated benefits of this combination therapy, recurrence is overwhelmingly
inevitable even in patients who respond positively to initial treatment.2 For complete
eradication of infiltrative cancer cells in surrounding healthy tissue, chemotherapy is
necessary. However, selection of appropriate drugs (typically alkylating agents such as
temozolomide, carmustine, lomustine, and procarbazine) is challenging, as the blood-brain
barrier (BBB) generally only allows passage of lipophilic small molecules and essential
nutrients from the bloodstream to the brain.4,5 This, combined with issues typical of most
small molecule chemotherapeutics (i.e., off-target toxicity, rapid clearance from the
bloodstream, and poor tumor selectivity), drives the development of new strategies for
efficacious treatment of glioblastoma.
Local treatment immediately following surgical resection represents a potential
alternative to systemic tumor treatment as a means of bypassing the BBB and delivering
chemotherapeutics directly to invasive cells in a sustained manner. Gliadel®, a
biodegradable carmustine-loaded polymer wafer, remains the only therapeutic approved
for local glioblastoma treatment to date. However, the clinical use of Gliadel ® is limited
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by side effects, including seizures, cerebral edemas, and intracranial bleeding, as well as
incomplete wafer degradation and wafer migration.6 Though ‘softer’ matrices, such as
drug-loaded hydrogels,7 may prove to be safe alternatives, noninvasive systemic treatments
which can cross the BBB hold potential for improving glioblastoma chemotherapy without
the complications inherent to surgical implants.
Temozolomide (TMZ), a bis(imidazotetrazine) heterocycle, is the first-line drug
used for treating glioblastoma, and, as such, research is devoted to enhancing its delivery
and efficacy. Administered orally, TMZ is a prodrug which releases a DNA alkylating
methyldiazonium cation upon decomposition at physiological pH, as shown in Figure
2.1.8,9 Alkylation occurs primarily at O6 positions of guanine residues, generating DNA
mismatch errors which lead to apoptosis.9 While TMZ crosses the BBB, its efficacy is
impeded by enzyme-mediated chemoresistance and hydrolytic instability: TMZ rapidly
degrades in vivo and exhibits a plasma half-life of <2 hours.10 As such, frequent dosing is
required to maintain suitable antitumor activity.8,9,11 Furthermore, its hydrolytic instability
complicates dosing, as TMZ degrades over time ex vivo when stored improperly.12–14 As
such, recent advances have focused on enhancing the stability of TMZ in solution and
improving its overall efficacy in glioblastoma tumors. Reported strategies to stabilize TMZ
include its co-crystallization with organic acids,14 encapsulation in injectable
nanomaterials,15,16 and conjugation to biocompatible polymer backbones.17,18 Covalent

pH 7.4, H2O
-CO2

DNA alkylating
agent

temozolomide (TMZ)

Figure 2.1: Decomposition of TMZ to the cytotoxic methyldiazonium cation.

17

conjugation to polymers offers significant advantages, including extending TMZ lifetime
in vivo, improving drug pharamacokinetics, allowing for high drug loading while retaining
aqueous solubility, and masking drug-related toxicity.19–21 Moreover, unlike conventional
polymer prodrugs, TMZ retains therapeutic activity when attached to polymers,
irrespective

of

the

conjugation

method.

This

chapter

extends

the

poly(2-

methacryloyloxyethyl phosphorylcholine) (polyMPC) platform utilized with other
hydrophobic drugs, as discussed in Chapter 1, using an innovative TMZ-methacrylate.22
Random and block copolymers bearing pendent TMZ moieties were prepared using this
monomer by reversible addition-fragmentation chain-transfer (RAFT) polymerization,
affording conjugates over a broad range of drug incorporations with narrow molecular
weight distributions. The effect of polymer architecture on aqueous solution assembly and
TMZ stability under physiological conditions was evaluated. Additionally, the antitumor
activity of the copolymers was tested in chemosenstive and chemoresistant glioblastoma
cell lines, and the mechanism and extent of cellular uptake was assessed using confocal
microscopy and flow cytometry, respectively. Finally, this polymer-drug platform was
expanded through the incorporation of redox-sensitive linkers between the polymer the
drug.23
The research presented in this chapter was conducted with Matthew Skinner, who
equally contributed to the synthesis and characterization of the non-redox polyMPC-TMZ
conjugates and who led experiments on the aqueous assembly properties of these polymers.
Additionally, cell uptake and viability studies were performed by Dr. Banishree Saha.
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2.2 Synthesis and Evaluation of PolyMPC-TMZ Conjugates
Scheme 2.1: Synthesis of TMZ-carboxylic acid (TMZ-COOH) and TMZ-methacrylate
(TMZ-MA).

Critical to this work is TMZ-methacrylate (TMZ-MA), prepared as shown in
Scheme 2.1. TMZ-carboxylic acid (TMZ-COOH) was synthesized by diazotization and
hydrolysis of the TMZ amide precurosor in nitrous acid using modification of a procedure
described by Stevens and co-workers.24 Esterification of TMZ-COOH was achieved by
carbodiimide-mediated coupling utilizing 2-hydroxyethyl methacrylate (HEMA) in the
presence of 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (EDC) and
catalytic 4-(dimethylamino)pyridine (DMAP). TMZ-MA was purified simply by aqueous
(A)
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Figure 2.2: 1H NMR spectrum (A) and UV-vis absorption spectrum (B) of TMZ-MA.
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extraction and isolated in 70-80% yields as a flaky white solid, with the expected molar
mass confirmed by fast-atom bombardment HRMS (HRMS-FAB) ([M + H]+: 308.0989
g/mol). In the 1H NMR spectrum of TMZ-MA, the reosnances corresponding to imidazole
(δ = 8.85 ppm) and methyltriazine (δ = 3.88 ppm) were observed (Figure 2.2A). The UVvis absorption spectra of TMZ (λmax = 325 nm) and TMZ-MA (λmax = 323 nm) were nearly
identical (Figure 2.2B), further confirming TMZ structural viability.
The RAFT-mediated copolymerization of polyMPC-TMZ conjugates was
achieved in 2,2,2-trifluoroethanol (TFE), a solvent was found to effectively solubilize both
monomers and preserve the TMZ chemical structure under polymerization conditions. 22
As shown in Figure 2.3, random copolymers P1-P4 were prepared by the copolymerization
of MPC and TMZ-MA, utilizing 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid and
4,4’-azobis(4-cyanovaleric acid) as chain-transfer agent (CTA) and radical initiator
species, respectively, at 70 °C TFE. Polymerizations targeted TMZ incorporations of 20,
(A)

ACVA, TFE, 70 C

P1-P4
TMZ-MA

(B)

ACVA, TFE, 70 C

P5

P6-P8

Figure 2.3: Synthesis of polyMPC-TMZ copolymers with random (A) and block (B)
copolymer architectures by RAFT polymerization of TMZ-methacrylate (TMZ-MA).
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25, 35, and 50 mole percent, respectively, and number-average number-average molecular
weight (Mn) values of approximately 30 kDa. Polymerizations were terminated at >85%
monomer conversion, as estimated by 1H NMR and achieved by 6 h of reaction time, by
exposure of air. Polymer products were purified by repeated precipitation from TFE into
tetrahydrofuran (THF), followed by centrifugal dialysis against aqueous 0.1 M HCl, a
dialysis solution selected to prevent TMZ degradation. Lyophilization of the product gave
random copolymers P1-P4 as pink solids (the color attributed to the dithioester chain end)
in 70-80% yields, after accounting for monomer conversion, which readily dispered in
water at concentrations of >40 mg/mL.
PolyMPC-TMZ conjugates were synthesized as diblock copolymers starting from
a polyMPC macro-CTA bearing a dithioester chain-end suitable for RAFT chain extension
with TMZ-MA (Figure 2.3). PolyMPC macro-CTA P5 was prepared by the
homopolymerization of MPC in TFE, targeting an Mn of 15 kDa and quenching
polymerization at <80% monomer conversion, as estimated by 1H-NMR spectroscopy. The
polymer product was precipitated into THF, dialyzed in water, and isolated by
lyophilization in 80% yield, after accounting for monomer conversion.

1

H-NMR

spectroscopy of polymer P5 showed resonances corresponding to chain-end phenyl protons
at 7.40-7.96 ppm (Figure 2.4A), confirming retention of the dithioester chain-ends. Chainend analysis, integrating the aromatic protons of the phenyl end groups vs. the PC
methylene (δ = 3.66-3.82 ppm) resonances, gave an estimated Mn of polymer P5 ranging
from 15.1-19.8 kDa with impressively low dispersity (Ð) values of 1.05-1.13 (as estimated
using GPC eluting with TFE relative to poly(methyl methacrylate) (PMMA) standards).
TMZ-containing block copolymers P6-P8 targeting drug loadings of 20, 26, and 36 mole
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Figure 2.4: Representative 1H NMR spectra: (A) polyMPC macro-CTA P5, (B) random
polyMPC-TMZ, and (C) block polyMPC-TMZ.
percent, respectively, were prepared by polymerizing TMZ-MA in TFE at 70 °C using
macro-CTA P5 and ACVA as the radical initiator. Monomer conversions of >90% were
achieved in approximately 4-8 hours, and the block copolymers were purified in similar
fashion to that of the random copolymers, and isolated as pink solids in >50 % yield.
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The structural integrity of the pendent TMZ moeities, a crucial feature for
preserving drug efficacy, was confirmed by NMR spectroscopy of copolymers P1-P4 and
P6-P8. In the 1H NMR spectra of polyMPC-TMZ random and block copolymers,
resonances corresponding to TMZ imidazole protons were observed at 8.53 and 8.72 ppm,
respectively (Figure 2.4B-C). Additional resonances at 3.92 (random) and 3.88 (block)
ppm are attributed to the TMZ methyltriazene protons. Importantly, these signals for the
polymer-bound TMZ are single, clean resonances for both copolymer architectures, with
no sign of degradation to the 5-aminoimidazole-4-carboxamide (AIC) by-product.

13

C

NMR spectroscopy further confirmed retention of the TMZ structure, with characteristic

(A)

(B)

P1
P2
P3
P4
Degraded TMZ

(C)

P6
P7
P8
Degraded TMZ

P4
P8

Figure 2.5: UV-vis absorption spectra of polyMPC-TMZ (A) and block (B) copolymers in
TFE at a concentration of 0.05 mg/mL. A representative spectrum of degraded TMZ in
shown in each compilation. Representative GPC chromatograms of polyMPC-TMZ
copolymers P4 and P8 eluting in TFE with RI detection (C).
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resonances of the methyltriazene moiety appearing at 38.2 and 38.5 ppm for the random
and block architectures, respectively. Moreover, UV-vis spectra of the copolymers in TFE,
shown in Figure 2.5A-B, exhibited an absorbance maximum at λ = 323 nm, characteristic
of the urea group of intact TMZ.
TMZ incorporations into the polyMPC-TMZ copolymers P1-P4 and P6-P8 were
estimated using 1H NMR spectroscopy, integrating signals from the TMZ imidazole and
PC trimethylammonium (δrandom = 2.86-3.29 ppm, δblock = 2.78-3.22 ppm) protons. For each
copolymer, numerous samples were prepared for in vitro evaluation in glioblastoma cell
lines. Characterized drug loading in these samples, summarized in Table 2.1, were in
excellent agreement with targeted values and exhibited minimal compositional variation.
Table 2.1: TMZ Drug Loading and Molecular Weight Characterization of PolyMPC-TMZ
Copolymers P1-P4 and P6-P8.
Targeted TMZ Measured TMZ
Theoretical
Mnc
Polymer Incorporation
Incorporationa
Đc
b
Mn (kDa)
(kDa)
(mol %)
(mol %)
P1

20

15-17

25.5-27.3

34.3-42.8

1.14-1.22

P2

25

23-26

26.8-29.7

39.4-42.1

1.21

P3

35

32-33

27.6-27.8

36.2-40.5

1.14-1.20

P4

50

47-50

28.3-29.2

40.6-46.4

1.15-1.28

P6

20

14-16

18.1-25.0

23.6-24.8

1.14-1.15

P7

26

24-25

19.4-26.9

22.6-29.6

1.09-1.19

P8

36

31-35

22.5-30.4

24.9-31.5

1.09-1.21

a

Estimated by 1H NMR. bDetermined from percent monomer conversion, which was
estimated by 1H NMR spectroscopy. cEstimated by GPC eluting with TFE, calibrated
against PMMA standards.
Additional syntheses targeted TMZ loadings of 65 and 50 mole percent for
copolymers with random and block architectures, respectively. While copolymers with
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such high drug loadings were synthetically accessible, their low water solubility made them
unsuitable for further evaluation.
The molecular weights of polyMPC-TMZ copolymers were estimated by GPC,
eluting in TFE and calibrated against PMMA standards. Representative chromatograms for
random and block copolymers P4 and P8, shown in Figure 2.5C, were relatively narrow
and distinctly monomodal. As shown in Table 5.1, polyMPC-TMZ random and block
copolymers were isolated with Mn values of 36.2-46.4 and 22.6-31.5 kDa, respectively,
and Ð values of 1.09-1.28. Copolymers of the same architecture were found to possess
similar estimated Mn values across multiple samples, demonstrating the excellent
reproducibility of this synthetic approach. Importantly, GPC chromatograms obtained with
UV detection at λ = 323 nm showed no evidence of residual TMZ-MA in any of the
copolymers.
Possessing both hydrophlic PC zwitterions and hydrophobic TMZ moeities,
polyMPC-TMZ copolymers were anticipated to form aqueous assemblies of much larger
hydrodynamic sizes than TMZ itself. Critical aggregation concentration (CAC) values of
polyMPC-TMZ copolymers were determined in pH 7.4 phosphate-buffered saline (PBS)
at 37 °C using dynamic light scattering (DLS);25 the absorption characteristics of TMZ
preclude using fluorescent (e.g., pyrene)26 or absorption (e.g., 1,6-diphenyl-1,3,5hexatriene)27 encapsulation assays to obtain CAC values. Representative plots of DLS
scattering intensity for solutions of P4 and P8 in PBS at polymer concentrations ranging
from 0.005-5 mg/mL are shown in Figure 2.6. Notably, block copolymer P8 exhibited a
sharp increase in scattering intensty at a critical concentration of approximately 0.48
mg/mL, indicating the onset of copolymer aggregation. Similar behavior was observed for
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(D)

(C)
Polymer

CACa
(mg/mL)

Hydrodynamic
Diameterb
(nm)

P6

0.70

33

P7

0.45

24

P8

0.48

38

P4

N/A

7

aCAC

values estimated in pH 7.4 PBS at 37 C using DLS.
diameters measured by DLS analysis of 1
mg/mL suspension in pH 7.4 PBS at 37 C

bHydrodynamic

100 nm

Figure 2.6: Aqueous assembly of polyMPC-TMZ copolymers: (A) representative
scattering intensities for suspensions of polymers P4 and P8 with varying polymer
concentrations in pH 7.4 PBS at 37 °C measured by DLS. For block copolymers P6-P8,
the CAC was estimated as the onset of increasing scattering intensity; (B) DLS plots of
polymers P6-P8 and P4 in pH 7.4 PBS (37 °C) at a concentration of 1 mg/mL; (D) CAC
values and hydrodynamic diameters for P6-P8 and P4 measured using DLS at 37 °C in pH
7.4 PBS; (D) representative cryo-TEM image of nanoparticles formed from polymer P8 in
water at a concentration of 1 mg/mL.
polymers P6 and P7 at concentrations of 0.70 and 0.45 mg/mL, respectively. CAC values
for P6-P8, summarized in Figure 2.6, were estimated as the onset of increasing scattering
intensity. In contrast, scattering intensity values for solutions of P4 remained relatively
constant at each polymer concentration, pointing to an indiscernible CAC for polyMPCTMZ random copolymers.
The hydrodynamic diameters of structures formed from P6-P8 in PBS at 37 °C
were estimated using DLS at a concentration of 1 mg/mL, above the CAC of each polymer.
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The DLS plots in Figure 2.6 show that polyMPC-TMZ block copolymers form monomodal
nanoparticles (dh = 24-38 nm) with no evidence of particle aggregation. Remarkably, these
block copolymers readily assembled in water into well-defined and narrowly dispered
aggregates without the need for intricate solution-assembly procedures (e.g., solventdirected assembly or thin film hydration).28–30 In contrast, a trimodal size distribution was
observed for random copolymer P4, which was dominated by the smaller structures (dh ~
7 nm). As expected, the hydrodynamic diameters of P1-P3 were similary small.
Suspensions of block copolymer P8 in pure water were cast on carbon-coated copper grids,
vitrified in liquid ethane, and visualized by cryogenic transmission electron microscopy
(cryo-TEM). As shown in Figure 2.6, P8 nanoparticles were observed as spherical
aggregates with discrete coronae composed of polyMPC. These nanoparticles exhibited a
narrow size distribution, with a mean diameter of 12.6 ± 2.8 nm. The larger diameter
obtained by DLS relative to cryo-TEM is attributed to the hydration layer of the hydrophilic
nanoparticle corona; similar overestimation by DLS relative to EM observations has been
reported for other polymer nanoparticles.31
The hydrolytic instability of TMZ leads to rapid decomposition under physiological
conditions, with reported half-lives in pH 7 PBS and blood plasma of only 1 and 1.8 hours,
respectively.10 This premature TMZ degradation leads to off-target hematoxicity and
reduces the concentration of TMZ available to cancer cells. Developing TMZ formulations
that stabilize the drug and prolong its half-life in solution is critical to augmenting efficacy.
The decompostion of TMZ was easily monitored by UV-vis spectroscopy: as TMZ
degraded, the absoption corresponding to the urea moiety of pristine TMZ (λ = 328-330
nm) decreased in intensity, as shown in Figure 2.7, and a new absorption attributed to the
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Figure 2.7: (A) Representative UV-vis cascade curves showing evidence of TMZ
degradation by a decrease in peak intensity at λ = 328-330 nm, corresponding to the TMZ
urea, to the AIC by-product, seen as an increase in peak intensity at λ = 265-267 nm; (B)
degradation profiles for TMZ, P1-P4, and P6-P8 incubated in pH 7.4 PBS at 37 °C; (C)
values of t1/2 estimated for TMZ, P1-P4, and P6-P8 from exponential fitting of decay
curves, as well as corresponding experimental timeframes.
amide group of the AIC by-product was observed at λ = 265-267 nm.14,32 To investigate
the impact of polymer conjugation, drug loading, and architecture on TMZ stability,
polyMPC-TMZ copolymers P1-P4 and P6-P8 were incubated at 37 °C in pH 7.4 PBS, and
compared to TMZ itself. UV-vis absorption spectra were recorded over time, and TMZ
degradation profiles were constructed from the absorption decrease at λ = 328-330 nm
(Figure 2.7). Half-life values for TMZ and the polyMPC-TMZ copolymers, summarized
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in Figure 2.7, were obtained from exponentional decay curves generated by plotting the
normalized absorbance (A/A0) as a function of incubation time. As shown in Figure 2.7,
TMZ degraded quickly in PBS, exhibiting a t1/2 of only 1.0 hour. The polyMPC-TMZ
random copolymers legthened TMZ half-life 2- to 3-fold, a finding that proved independent
of mole percent TMZ incorporation for the random copolymers. Polymer architecture had
a marked effect on TMZ solution stability, with block copolymers P6, P7, and P8 raising
t1/2 values to 12.8, 18.9, and 19.1 hours, respectively. In contrast to the random copolymers,
increasing TMZ incorporation from 16-17 to 23-26 mole percent led to a dramatic increase
of t1/2 values; however, additional TMZ incorporation beyond 26 mole percent did not
further improve solution stability. While TMZ in the P1-P4 polymers degraded almost
entirely within 24 hours, significant amounts of TMZ (18-37%) incorporated into the block
copolymers remained intact, even after incubation at pH 7.4 and 37 °C for 33 hours. These
results highlight the role of polymer architecture in enhancing TMZ stability in an aqueous
environment. Such improvements in TMZ stability enabled by the polyMPC-TMZ
platform are comparable, if not superior, to other delivery systems,17-18 while remaining
synthetically accessible.
In addition to stabilizing TMZ by polymer conjugation, TMZ uptake into block
copolymers was demonstrate. Aqueous suspensions of block copolymer amphiphiles—
polyMPC-TMZ block copolymer P7 and a poly(MPC-b-butyl methacrylate) (polyMPCBMA) copolymer with 28 mole percent BMA—were used to solubilize free TMZ in pH
7.4 PBS at polymer concentrations of 5 mg/mL. By eye, TMZ-contaning polymer P7
dissolved TMZ more rapidly than the polyMPC-BMA surfactant. Furthermore, the
polyMPC-TMZ block copolymer suspended free TMZ completely at a drug concentration
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of 4 mg/mL, while polyMPC-BMA, under the same conditions, left residual (undissolved)
TMZ. These TMZ-block copolymer suspensions were diluted approximately 400 times and
incubated at 37 °C, with TMZ degradation monitored by UV-vis spectroscopy. Under these
conditions, the solution stability was not significantly extended in comparison to free
TMZ—half-lives of 1.3 and 1.4 hours were measured for TMZ suspensions prepared using
P7 and polyMPC-BMA, respectively. TMZ stability was also examined at a polyMPCBMA concentration well above the CAC (1 mg/mL), as estimated using a pyrene
fluoresence assay.26 Despite solubilization and encapsulation of TMZ into the hydrophobic
core of the block copolymer aggregates, the TMZ t1/2 was extended minimally to 1.8-2.7
hours. A comparable experiment was not feasible for the polyMPC-TMZ conjugates, as
TMZ groups pendent to the polymer backbone saturated the UV-vis detector at this
concentration (i.e., 1 mg/mL) and prevented absorbance measurements of encapsulated
TMZ. These results suggest that polymer-TMZ conjugation is superior to encapsulation for
significantly enhancing TMZ solution stability.
The polyMPC-TMZ conjugate platform, unlike conventional prodrugs, does not
require triggered release of covalently conjugated TMZ moieties for antitumor activity. As
such, copolymer internalization is likely necessary for efficacious treatment, by enabling
release of methyldiazonium cations near cellular DNA. To investigate cellular uptake and
intracellular accumulation, fluorescently labeled random copolymers with 16 and 51 mole
percent TMZ (P9 and P10, respectively), and block copolymers with 11 and 33 mole
percent TMZ (P11 and P12, respectively), were synthesized, incorporating ~ 1 mole
percent of fluorescein methacrylate to allow microscopic visualization. Cellular uptake was
investigated in U87MG cells incubated for 2 h with fluorescein-labeled polyMPC or
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polyMPC-TMZ copolymers, then visualized by confocal microscopy at a set camera
exposure time. PolyMPC-TMZ copolymers exhibited increased intracellular accumulation
Lysosome stain

Fluorescein

Merge

Merge + white light

P9

P13

Control

Nucleus stain

P10

(A)

P12

P11

(B)

Figure 2.8: Fluorescence micrographs of U87MG cells incubated for 2 h with fluoresceinlabeled polyMPC (P13), random copolymers P9 (A) and P10, and block copolymers P11
(B) and P12. Cell nuclei were stained with DAPI (blue), lysosomes were stained with
Lysotracker Red (red), and fluorescent copolymers appear as green. White arrows indicate
overlay of red and green fluorescence, suggesting copolymer localization in lysosomes.
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compared to polyMPC alone, suggesting that the pendent hydrophobic TMZ moieties
promoted cellular uptake into the cytoplasm (Figure 2.8). Similar behavior has been
reported previously: Goda et al. demonstrated that, while polyMPC has low cellular
permeability on its own, the incorporation of hydrophobic units (e.g., butyl methacrylate)
to form amphiphilic MPC-based copolymers increased cell penetration.33 While polyMPC
and polyMPC-TMZ conjugates did not localize in the nucleus, as evidenced by the lack of
overlay with DAPI-stained regions, the polymer-drug conjugates did exhibit perinuclear
localization. Furthermore, both the fluorescently labeled polyMPC copolymer and
polyMPC-TMZ conjugates co-localized in lysosomes, marked by significant overlay with
red-stained regions, as shown in Figure 2.8. It is hypothesized that polymer-drug
conjugates, following endosome-mediated uptake into the cell, localize in the lysosomes
and efflux into the cytosol, allowing for methyldiazonium cation release near the nucleus
for DNA methylation.
Cellular uptake of polymer-drug conjugates was quantified by flow cytometry:
fluorescently labeled polyMPC (P13), P9-P10, and P11-P12 were incubated at
fluorescein-equivalent concentrations in U87MG cells for 2 h, after which the relative
intracellular fluorescence intensities were determined on a fluorescence plate reader, as
compiled in Figure 2.9. In agreement with qualitative fluorescence microscopy
observations, polyMPC-TMZ intracellular accumulation was far greater than that of
polyMPC itself, indicating that pendent TMZ moieties enhanced polymer uptake into
glioblastoma cells. Interestingly, block copolymers P11-P12 achieved markedly higher
uptake than the random copolymer analogues, despite the segregation of TMZ into core
domains that have minimal interaction with cell membranes. While this result was
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Figure 2.9: Intracellular abundanceo l y of
polyMPC (P13) and polyMPC-TMZ conjugates
p
(random copolymers P9 and P10; block copolymers P11 and P12) after 2 h incubation at
fluorescein equivalent concentrations in U87MG cells.

unexpected, previous reports on the effect of monomer distribution on cellular
internalization have shown that uptake is largely influenced by polymer chemistry and not
copolymer architecture itself.34–36
The antitumor activity of polyMPC-TMZ copolymers was investigated in TMZsensitive (i.e., U87MG) and TMZ-resistant (i.e., T98G) glioblastoma cells. These cell lines
have been utilized extensively for testing TMZ cytotoxicity,37–41 as well as TMZcontaining delivery systems.18,42,43 In dose-response assays in the literature, an unusually
broad range of IC50 values have been reported for TMZ, spanning from 10-500 µM for
U87MG cells and 250-1600 µM for T98G cells.41

Other small molecule

chemotherapeutics (e.g., doxorubicin)44–48 have comparatively narrow ranges of reported
IC50 values; the wide variation seen with TMZ likely arises from differences in
experimental protocols. Moreover, the poor aqueous solubility and hydrolytic instability of
TMZ add complexity and likely increase variability in cell culture experiments, as aqueous
TMZ solutions must be added to cells immediately after preparation. Recognizing the
importance of handling TMZ in such a way as to accurately measure its cytotoxicity,
aqueous exposure was kept to a minimum prior to cell culture experiments.
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The cytotoxicity of the polyMPC-TMZ conjugates was evaluated with U87MG and
T98G glioblastoma cells. Free TMZ and polyMPC-TMZ copolymers were incubated at
TMZ-equivalent concentrations with U87MG or T98G cells for 6 days, with polyMPC
serving as a negative control. Cell viability was determined using a CellTiter-Glo® assay
to generate dose-response curves (Figure 2.10). Free TMZ exhibited IC50 values of 192 ±
72 μM and 418 ± 116 μM in U87MG and T98G cells, respectively. The IC50 values for the
polyMPC-TMZ copolymers, summarized in Figure 2.10, were 7- to 10-fold higher than
the free TMZ values in both cell lines. While polyMPC-TMZ lacks a responsive polymerto-drug linker and, as such, is not a typical polymer prodrug, reduced cytotoxicity of
polymer-bound drugs vs. free drugs has been noted in many examples of polymer-drug
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Figure 2.10: Cell viability of polyMPC-TMZ random (A) and block (B) copolymers in
U87MG (top) and T98G (bottom) glioblastoma cells; (c) IC50 values for free TMZ and
polyMPC-TMZ copolymers in both cell lines (± indicates standard deviation).
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conjugates and is advantageous for achieving higher maximum tolerated doses in vivo.44,49–
52

Thus, as expected, higher polyMPC-TMZ copolymer concentrations were necessary to

induce cytotoxicity in both cell lines. Moreover, a plateau in IC50 values was reached once
a critical TMZ incorporation was achieved (>20 mole percent): P1 and P6 had significantly
higher IC50 values, as compared to P2-P4 and P7-P8, respectively. Polymer architecture
appeared to have no effect on the cytotoxicity of polyMPC-TMZ copolymers in
chemosensitive U87MG cells. However, block copolymers with sufficiently high TMZ
loading (>20 mole percent) exhibited significant (i.e., 54-82%) reduction in IC50 values in
chemoresistant T98G cells, relative to the random copolymer conjugates with comparable
drug loadings. This improvement in anti-glioblastoma activity is likely due to the enhanced
TMZ solution stability and the increased cellular uptake afforded by the block copolymer
architecture relative to the random structures. While these copolymers showed higher IC50
values than free TMZ, they remained efficacious in both chemosensitive and
chemoresistant cell lines. This, coupled with their favorable solution stability properties,
makes polyMPC-TMZ conjugates promising for allowing higher dosing and increased
antitumor efficiency in future in vivo work.

2.3 Redox-Responsive PolyMPC-TMZ Conjugates
While the polyMPC-TMZ copolymers demonstrated enhanced TMZ solution
stability and efficacious in vitro antitumor activity, this delivery platform was further
expanded by preparing responsive polymer-drug conjugates containing redox-sensitive
disulfides as the polymer-to-TMZ linkages. Polymer prodrugs utilizing disulfide linkers
have been examined for chemotherapeutics,50,53,54 taking advantage of the high reducing
potential of intracellular environments, relative to extracellular space,55 to promote
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triggered and localized drug release. Such degradable linkers will provide a mechanism for
releasing intact TMZ from the polymer backbone in environments with high concentrations
of reducing agents.
Scheme 2.2: Synthesis of disulfide-containing TMZ-methacrylamide (TMZ-Ma).

i) di-tert-butyl dicarbonate, triethylamine, MeOH; ii) methacryloyl chloride, triethylamine,
dichloromethane; iii) trifluoroacetic acid, dichloromethane; iv) TMZ-COOH, N-(3dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride, 4-(dimethylamino)pyridine,
triethylamine, dichloromethane.
Seeking to produce releasable TMZ prodrugs, disulfide-containing TMZ monomer
(TMZ-Ma) was synthesized using the strategy shown in Scheme 2.2. The methacrylamide
precursor was prepared following a modified literature procedure,56 then coupled to TMZcarboxylic acid using carbodiimide-mediated conditions to give TMZ-Ma as a white
powder in 80-85% yield. Attempts to synthesize a comparable disulfide-containing TMZmethacrylate monomer were unsuccessful due to low coupling efficiency between the
carboxylic acid and the corresponding disulfide-containing hydroxyethyl methacrylate.
Redox-responsive polyMPC-TMZ random copolymers P14 and P15 were synthesized by
RAFT polymerization, using conditions similar to those described for polymers P1-P4,
targeting 15 and 50 mole percent TMZ incorporation, respectively (Figure 2.11A).
Notably, the lower solubility of TMZ-Ma in TFE required more dilute polymerization
conditions (0.75 M) relative to comparable polymers without disulfide linkers (1.0 M).
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Figure 2.11: (A) Synthesis of random polyMPC-TMZ copolymers by RAFT
polymerization of TMZ-methacrylamide (TMZ-Ma). (B) Representative GPC
chromatograms of P14-P15 eluting in TFE with UV detection.
Redox-responsive copolymers P14 and P15 were isolated in 73 and 60% yields,
respectively. TMZ incorporations were characterized by 1H NMR spectroscopy, and
copolymer molecular weights were estimated using GPC eluting in TFE, calibrated against
PMMA standards (Table 2.2). The observation of an absorption maxima at λ = 326 nm in
the UV-vis spectra of polymers P14 and P15 confirmed that pendent TMZ moieties did
not degrade during polymerization (Figure 2. 11B). While chain-extension from macroCTA P5 was possible, the poor solubility of disulfide-containing TMZ-Ma in aqueous and
organic solvents precluded purification and isolation of the resulting block copolymers in
appreciable yields. As such, our investigation of redox-sensitive polyMPC-TMZ prodrugs
focused on random copolymers P14 and P15.
Table 2.2: TMZ Drug Loading and Molecular Weight Characterization of RedoxResponsive PolyMPC-TMZ Copolymers P14-P15.
Target
Measured
Theo. Mnb
Polymer
TMZ
TMZ
Mnc
Đc
(kDa)
(mol%)
(mol%)a
P14
P15
a

1

15

12

27.6

36.8

1.17

50

43

31.2

39.3

1.14

b

Estimated by H NMR spectroscopy. Theoretical Mn determined from percent monomer
conversion, as estimated by 1H NMR spectroscopy. cEstimated by GPC eluting with TFE,
calibrated against PMMA standards.

37

The hydrolytic stability of the disulfide-containing polyMPC-TMZ random
copolymer P14 was investigated by UV-vis spectroscopy at varying concentrations of
glutathione (GSH) in pH 7.4 PBS. The concentrations 2 μM GSH and 1 mM GSH were
specifically selected to reflect the redox environments of human blood plasma and
glioblastoma tumor tissue, respectively.57–59 Copolymer P14 was incubated either in pure
PBS buffer or GSH-containing PBS buffer at 37 °C, and the UV-vis absorption spectra
were collected over 24 h. As previously described, degradation profiles were generated
from the absorption decrease at λ = 328-330 nm, corresponding to the TMZ urea, and
exponential decay curves were constructed by plotting the normalized absorbance (A/Ao)
against incubation time. As with P1 and P4 (the random copolymers without disulfide
linkers), polymer conjugation extended the TMZ solution stability at physiological pH and
temperature: the t1/2 for P14 was 3.7 h in pure PBS buffer, compared to 3.1 h for P1. The
TMZ solution stability did not change significantly at 2 μM GSH, with P1 exhibiting a t1/2
of 3.6 h, suggesting that the disulfide-containing copolymers will retain slow TMZ
decomposition in circulation relative to TMZ itself. Notably, increasing the GSH
concentration to 1 mM halved the t1/2 to 1.7 h, which is attributed to the glutathionemediated reduction of disulfide polymer-to-drug linkers and subsequent release of small
molecule TMZ from the polymer backbone.
The cytotoxicity of disulfide-containing polyMPC-TMZ copolymers P14 and P15,
at TMZ-equivalent concentrations, was evaluated in U87MG cells under GSH-free (0 mM
GSH) and GSH-rich conditions (1 mM GSH), to mimic glioblastoma tumor tissue
environments. As controls, cells were incubated for 6 days with free TMZ and TMZ-thiol,
one of the possible by-products of glutathione-mediated disulfide exchange. As shown in
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Figure 2.12, dose-response curves were generated for each glutathione concentration,
giving IC50 values for free TMZ, TMZ-thiol, and disulfide-containing polyMPC-TMZ
conjugates P14-P15. The cytotoxicity of copolymers P14 and P15 was dependent on the
amount of GSH in the media: the IC50 values decreased, respectively, from 1999 and 2592
μM in non-glutathione-enriched media to 1308 and 756 μM in 1 mM GSH media,
indicating that TMZ release from the polymer backbone led to a potentiation of
cytotoxicity. These results suggest the potential benefit of disulfide-containing polyMPCTMZ copolymers with built-in polymer-to-drug linkers for redox-responsive release to
treat glioblastoma tumor cells.
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Figure 2.12: Dose-response curves for U87MG cells treated with TMZ, TMZ-thiol, and
polyMPC-TMZ conjugates (P14 and P15) in unmodified (A) and GSH-enriched (B)
media; (C) IC50 values for free TMZ, TMZ-thiol, and polyMPC-TMZ copolymers at
different glutathione concentrations (± indicates standard deviation); (D) a proposed
mechanism for triggered release of TMZ in the presence of in vivo reducing agents, such
as glutathione.
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2.4 Conclusions
In summary, the first-line chemotherapeutic of glioblastoma, TMZ, was
successfully incorporated into a library of polyMPC-TMZ conjugates by controlled free
radical polymerization. The direct conjugation of TMZ to the polymer backbone, through
a TMZ-containing methacrylate, allowed for the preparation of polyMPC-TMZ conjugates
having a wide range of drug loadings which exhibited enhanced hydrolytic stability
compared to free TMZ. Copolymer architecture played a significant role in drug efficacy,
with the block copolymers showing the formation of well-defined nanostructures, higher
intracellular abundance, and lower IC50 values in glioblastoma cells, compared to the
polyMPC-TMZ random copolymers. Degradable polyMPC-TMZ copolymers, prepared
with a disulfide polymer-to-drug linker for redox-triggered TMZ release, likewise
demonstrated favorable aqueous TMZ stability and cytotoxicity against U87MG cells. The
enhanced hydrodynamic sizes and solution stability, as well as the demonstrated antiglioblastoma activity, of these polyMPC-TMZ conjugates suggest their suitability for
future in vivo experiments.
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CHAPTER 3
MULTIDRUG POLYMER ZWITTERIONICS FOR OVERCOMING
CHEMORESISTANCE

3.1 Introduction
Glioblastoma is a highly aggressive and infiltrative central nervous system (CNS)
cancer which affects over 100,000 patients annually. The standard-of-care for glioblastoma
involves a combination of surgical resection, radiation, and chemotherapy, but this
extensive treatment only affords an average survival time of 12-15. Radiotherapy and
chemotherapy remain essential components of treatment, due to the complexities of tumor
resection and the infiltrative nature of glioblastoma cells.1 Temozolomide (TMZ) is the
first-line chemotherapeutic for treatment glioblastoma. Administered orally, TMZ is a
lipophilic prodrug which is activated at physiological pH to release a DNA methylating
agent which preferentially methylates the O6 position of guanine and adenine residues.2,3
As with other small molecule chemotherapeutics, TMZ is limited by rapid decomposition
(with a reported half-life, t1/2, of 1.8 h in blood plasma4) and renal clearance. Of particular
concern is natural TMZ chemoresistance mediated by native O6-methylguaninemethyl
transferase (MGMT), a suicide enzyme which irreversibly dealkylates DNA and precludes
effective treatment (Figure 3.1).2,5,6 As a result, tumor occurrence is often inevitable in
patients, even those who initially respond well to TMZ administration.7
Clinical trials have demonstrated that dose-dense TMZ schedules may deplete MGMT
activity, and protracted dosing regimens may restore TMZ efficacy in patients with
recurrent glioblastoma.8–12 With small molecule TMZ, these regimens are associated with
dose-limiting toxicity, but the use of a polymer-drug platform which extends TMZ
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MGMT

MGMT

Figure 3.1: Mechanism for the irreversible repair of methylated DNA by the MGMT
enzyme.
bioavailability and masks this off-target toxicity may overcome these shortcomings.
Additionally, enzymatic chemoresistance may be overcome through the use of MGMT
inhibitors which irreversibly deactivate MGMT following dealkylation or disulfide
exchange.13,14 Of particular interest for the depletion of MGMT activity are O6benzylguaninde (O6-BG), glutathione (GSH), or disulfiram (DSF).15–17 While O6-BG is a
potent MGMT inhibitor which has been shown to enhance the activity of alkylating agent
chemotherapeutics, its use is also associated with dose-limiting side effects.13,15,18,19
Disulfiram, while a less potent inhibitor, may provide therapeutic efficacy while limiting
off-target toxicity in combination with TMZ.17
Gemcitabine (GEM, dFdC, 2’,2’-difluorodeoxycytidine) is a nucleoside analogue
which is commonly administered for breast, ovarian, pancreatic, and non-small-cell lung
cancers.20,21 GEM uptake into cells is mediated by nucleoside transporters and activated by

Figure 3.2: Structures of gemcitabine (GEM) and its phosphorylated active form, GEM
triphosphate (dFdCTP).
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three phosphorylation events to become GEM

triphosphate (dFdCTP) (Figure 3.2).

Following phosphorylation, GEM triphosphate is incorporated into DNA during
replication and inhibits DNA chain extension, leading to apoptosis.21,22 Additionally, GEM
and its metabolite difluorodeoxyuridine (dFdU) are potent radiosensitizers, even at low
concentrations with brief exposure times.23–25 In a Phase II clinical trial, concomitant
radiotherapy-GEM was found to be well-tolerated in patients with newly diagnosed
glioblastoma, and disease control was obtained in >77% of patients with methylated and
unmethylated MGMT promoter.26 Polymer zwitterions which incorporate GEM and/or
TMZ may serve as potent therapeutics which multiple mechanisms of action well-poised
to overcome natural chemoresistance in patients and limit or prevent tumor recurrence.
z

This chapter describes attempts at synthesizing polymers which are intended to

overcome MGMT resistance, including polyMPC conjugates which incorporate
disulfiram, pendent TMZ moieties with multiple methods of attachment, and gemcitabine.
These materials are envisioned as staggered release therapeutics, which release drug over
multiple stages (Figure 3.3). The initial preparation of polyMPC-PDS-TMZ copolymers
were performed in collaboration with Matthew Skinner. While some of these materials

Stage 2 Drug
Release

Stage 1 Drug
Release

Figure 3.3: General schematic representing the staggered release concept, where polymer
zwitterion-drug conjugates release drugs over multiple stages.
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were synthetically inaccessible, polyMPC-TMZ conjugates containing disulfide-linked
TMZ were prepared, and drug release from the polymer backbone was evaluated in
multiple buffer systems to mimic various physiological conditions. Additionally,
copolymers of MPC and GEM were prepared and spectroscopically characterized. It is
envisioned that these materials are promising candidates for future in vitro and in vivo
testing against glioblastoma tumors.

3.2 Synthesis of PolyMPC-TMZ Copolymers with Pyridyl Disulfide
Key to this work is the use of a pyridyl disulfide (PDS) monomer, which can be
utilized in post-polymerization disulfide exchange reactions to incorporate additional
therapeutic moieties into polyMPC-TMZ structures. This exchange proceeds under mildly
acidic conditions, thus preserving the TMZ structure. PDS-methacrylate (PDS-MA) was
prepared through a two-step reaction, following a modified literature procedure, with yields
of 50% over two steps. Fittingly, PDS-MA has broad solvent solubility suitable for reverse
addition-fragmentation chain-transfer (RAFT) polymerization conditions with zwitterionic
and TMZ-containing monomers (e.g., methanol and 2,2,2-trifluoroethanol (TFE)).
The synthesis of polyMPC-PDS-TMZ random and block copolymers is shown in
Figure 3.4. A random polyMPC-PDS-TMZ copolymer (P16) targeting 25 mole %
incorporation each of PDS and TMZ was prepared by co-polymerizing MPC, PDS-MA,
and TMZ-methacrylate (TMZ-MA), using 4-cyano-4-(phenylcarbonothioylthio)pentanoic
acid and 4,4’-azobis(4-cyanovaleric acid) (ACVA) as the chain-transfer agent (CTA) and
radical initiator species, respectively (Figure 3.4A). Polymerizations were performed in
TFE at 70 °C and quenched at high monomer conversion (>85%), as quantified by 1H
NMR, by opening to air. Copolymer P16 was purified by repeated precipitation from
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(A)

P16

(B)

P17

P18

Figure 3.4: Synthesis of polyMPC-PDS-TMZ copolymers with random (A) and block (B)
copolymer architectures by RAFT copolymerizations of TMZ-methacrylate (TMZ-MA)
and PDS-methacrylate (PDS-MA).
minimal TFE into tetrahydrofuran (THF), followed by centrifugal dialysis against 0.1 M
HCl to remove unreacted monomers. Lyophilization of the product gave P16 as a pink
solid in 60% yield, accounting for monomer conversion.
A polyMPC-PDS macro-CTA (P17) for use in preparing polyMPC-PDS-TMZ
block copolymers was prepared by the co-polymerization of MPC and PDS-MA in TFE
(Figure 3.4B). Polymerizations targeting a molecular weight (Mn) of 15 kDa were
performed in TFE at 70 °C and quenched at <90% monomer conversion to preserve the
chain-ends for subsequent extension with TMZ-MA. 1H NMR spectroscopy of the
polyMPC-PDS macro-CTA showed resonances corresponding to the chain-end phenyl
protons (δ = 7.64 ppm), confirming retention of the living character of the polymers. Chain-
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end analysis—comparing the aromatic protons of the dithioester phenyl end groups, the PC
methylene protons (δ = 3.80 ppm), and pyridyl disulfide phenyl protons (δ = 7.47 ppm)—
gave an estimated Mn of 22.0-25.5 kDa. Gel permeation chromatography (GPC) eluting in
TFE, using poly(methyl methacrylate) (PMMA) standards, gave low dispersity (Đ) values
of 1.08-1.13. TMZ-containing block copolymers (P18) targeting 25 mole % TMZ-MA
incorporation were prepared by polymerizing the monomer in TFE at 70 °C using P17 as
the macro-CTA and ACVA as the radial initiator. As with polyMPC-TMZ copolymers
described in Chapter 2, monomer conversion of >85% were achieved in 4 h while
preserving the structure of pendent TMZ moieties. Copolymer P18 was purified using the
same procedure as detailed for copolymers P16-P17, giving pink solids isolated in 55-60%
yields, relative to converted monomer. 1H NMR and GPC characterization of copolymers
P16-P18 is shown in Table 3.1.
Table 3.1: PDS and TMZ Drug Loading and Molecular Weight Characterization of
Copolymers P16-P18.
PDSa
TMZa
Mna
Mnb
Mwb
Sample
Đb
(mole %) (mole %)
(kDa)
(kDa)
(kDa)

a

P16

21-22

13-14

20.4-24.9

30.9

34.9

1.13

P17

18-22

-

14.0-20.1

22.0-25.5

23.9-29.1

1.08-1.13

P18

13-14

24-25

27.1

25.8

28.0

1.08

1

b

From H NMR; from GPC (eluting in TFE with PMMA standards).
Pendent TMZ incorporation and structural integrity following polymerization was

confirmed by 1H NMR and UV-vis spectroscopies. In the 1H NMR spectra of P16 and P18,
resonances corresponding to TMZ imidazole protons were observed at δ = 8.57-8.92 ppm.
Importantly, these peaks were broad and clean, indicating successful incorporation into the
backbone, complete removal of unreacted monomer, and a lack of drug degradation to the
5-aminoimidazole-4-carboxamide (AIC) by-product. UV-vis spectroscopy in TFE further
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confirmed retention of the TMZ structure, as both copolymer architectures exhibited an
absorbance maximum at λmax = 327-330 nm, attributed to the urea group of intact TMZ.

3.3 Attempts at Overcoming Enzymatic Resistance to Chemotherapeutics
While O6-benzylguanine is a potent inhibitor of MGMT, clinical trials have
demonstrated that its combined use with TMZ is associated with dose-limiting toxicity.18
As such, less potent alternatives like glutathione and disulfiram (DSF) may prove to be
more effective overall and safer for patients, while retaining anti-MGMT activity.16,17 For
this work, DSF was selected as the MGMT inhibitor to be incorporated into polyMPC-

(A)

P19

P18

(B)

P16

P20-P21

Figure 3.5: Disulfide exchange of P18 (A) and P16 (B) with sodium
diethyldithiocarbamate trihydrate (SDT) to yield DSF-containing copolymers P19-P21.
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TMZ structures, and a disulfiram precursor (sodium diethyldithiocarbamate trihydrate
(SDT)) was utilized in disulfide exchange reactions with PDS-containing copolymers to
this end (Figure 3.5). The disulfide exchange of P17 with excess SDT was conducted in
either TFE with catalytic acetic acid or aqueous 0.1 M HCl at a polymer concentration of
50 mg/mL. While the starting polymer solutions were pink (due to the dithioester chain
ends), the reaction color rapidly changed to orange upon product of the yellow thione byproduct. Crude polymers were purified by precipitation into THF and dialysis against RO
water, giving P19 as pink solids in 90% yields. 1H NMR spectroscopy confirmed the
successful removal of PDS groups, as well as the introduction of resonances associated
with DSF at δ = 1.28-1.46 ppm (Figure 3.6).

DSF

Figure 3.6: Representative overlayed 1H NMR spectra demonstrating complete PDS
exchange following disulfide exchange of polyMPC-PDS (P17) with DSF to yield
polyMPC-DSF (P19).
The disulfide exchange of P16 with SDT was similarly attempted in TFE with
catalytic acid or in aqueous 0.1 M HCl. However, TMZ degradation was evident during
both reactions, which rapidly turned opaque and red/brown in color (a change associated
with AIC production). Following polymer purification, as detailed for P19, UV-vis
spectroscopy confirmed TMZ degradation (Figure 3.7).
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Figure 3.7: UV-vis spectra of P20 (left) and P21 (right) in TFE following disulfide
exchange. Dashed red boxes represent areas indicative of TMZ degradation.
3.4 Synthesis of Redox-Responsive PolyMPC-TMZ
Previous attempts at preparing polyMPC-TMZ conjugates having redox-responsive
release of TMZ utilized a novel TMZ-methacrylamide (TMZ-Ma) containing a disulfide
linker. This strategy allowed for the direct incorporation of TMZ into the polymer structure
during polymerization. However, the low solubility of TMZ-Ma in TFE precluded the
formation of block copolymers, and in random copolymer systems the incorporation of
TMZ was lower than the feed ratio.27 Using PDS-containing copolymers, polyMPC-TMZ
copolymers with TMZ incorporated both through a methacrylate linker and a redoxresponsive disulfide linker can be prepared by facile post-polymerization conjugation.
Random and block copolymers of polyMPC-dsTMZ-TMZ were prepared by
disulfide exchange of P16 and P18 with TMZ-thiol in acidic conditions. Briefly, P16 or
P18 were dissolved in aqueous 0.1 M HCl at a concentration of 50 mg/mL and reacted at
room temperature with TMZ-thiol, at an approximate molar equivalence of 5:1 to pendent
PDS groups. The crude polymers were purified by repeated precipitation from minimal
TFE into THF, following by centrifugal dialysis against aqueous 0.1 M HCl. Polymers P22
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P22

P23

Figure 3.8: Structures of random (P22) and block (P23) polyMPC-dsTMZ-TMZ
copolymers.
(random) and P23 (block) were isolated as pink solids by lyophilization in 50-70% yields
(structures shown in Figure 3.8). 1H NMR spectroscopy showed complete removal of PDS
groups and the introduction of additional TMZ imidazole protons at δ = 8.73-8.84 ppm
(Figure 3.10). GPC eluting in TFE with PMMA standards showed the retention of low
dispersity (Đ) values (1.14-1.15) following disulfide exchange and purification. The final
TMZ incorporations are summarized in Table 3.2.
Table 3.2: TMZ Drug Loading and Molecular Weight Characterization of Copolymers
P22-P23.
TMZ,
TMZ,
Mnb
a
Sample
disulfide
methacrylatea
Đb
(kDa)
(mole %)
(mole %)
P22
P23
a

1

22

27

32.5

1.15

14

24

26.3

1.14

b

From H NMR; from GPC (eluting in TFE with PMMA standards).
The rapid degradation of TMZ in physiological conditions—with reported half-life

(t1/2) values of 1 and 1.8 h in pH 7.4 phosphate-buffered saline (PBS) and blood plasma,
respectively4,27—leads to off-organ toxicity and reduces the chemotherapeutic efficacy in
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patients. Random and block copolymers of polyMPC-TMZ significantly enhance the
stability of TMZ in aqueous solutions: 2-3 h and 12-19 h for the random and block
copolymers, respectively. Moreover, preliminary examinations of redox-responsive
polyMPC-TMZ copolymers exhibited degradation kinetics dependent on the reducing
environment, with higher reducing agent concentrations leading to reduced t1/2 values.27
The decomposition of TMZ in conjugates P22-P23 was monitored by UV-vis
spectroscopy, tracking the absorption peak corresponding to the urea moiety of TMZ (λ =
328-330 nm) over time as it decreased in intensity.28,29 To demonstrate the dependence on
the reducing environment, copolymers were incubated at 37 °C in pH 7.4 PBS with and
without 3 mM dithiothreitol (DTT). As shown in Figure 3.10, the TMZ solution stability
of P22 did not significantly change upon the introduction of a reducing agent,
demonstrating a t1/2 of 2.5 h compared to 2-3 h for comparable polyMPC-TMZ conjugates
without disulfide linkers. Notably, in the presence of DTT, conjugate P23 exhibited a
drastically reduced t1/2 value of 3.2 h, down from 18-19 h. This decrease is attributed to the

Normalized Absorbance (A/A0)

1.0

TMZ
P2
P7
P22 + 3 mM DTT
P23 + 3 mM DTT

0.8

0.6

0.4

0.2

Sample

t1/2
(h)

TMZa

1

P2a

2-3

P7a

18-19

P22

2.5

P23

3.2

0.0
0

5

10

15

20

25

Time (h)

Figure 3.9: Left: Degradation profiles for TMZ, P2, P7, and P22-P23 with 3 mM DTT.
(aDenotes data from Chapter 2). Right: Values of t1/2 estimated from exponential fitting of
decay curves.
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DTT-mediated reduction of the disulfide linker and subsequent release of small molecule
TMZ from the polymer.
TMZ release from copolymers P22-P23 was monitored by dialysis, where 400-500
μL of polymer solution was transferred to a dialysis cassette (MWCO 3.5 kDa) and
dialyzed against pH 7.4 phosphate-buffered saline (PBS), pH 7.4 PBS with 3 mM DTT,
pH 4.5 citrate buffer, or pH 4.5 citrate buffer with 3 mM DTT (225 mL) in a closed
container. Two buffer systems were selected to monitor TMZ release under physiological
conditions (pH 7.4 PBS) and under conditions which prevent TMZ degradation (pH 4.5).
The samples were incubated at 37 °C, and aliquots were removed from the external medium
and replaced with fresh buffer at predetermined time points. TMZ release was estimated
by UV-vis spectroscopy, specifically tracking the peak at λTMZ = 329 nm over time.
Additionally, in pH 7.4 PBS systems, the release of the AIC by-product was tracked by
monitoring the peak at λAIC = 267 nm. All drug release curves are shown in Figure 3.10.
The % of Maximum TMZ or AIC was calculated as the concentration of TMZ/AIC in the
aliquot relative to the maximum TMZ or AIC placed into the cassette, a method which does
not take into account TMZ degradation over time at pH 7.4.
Free TMZ was dialyzed against pH 4.5 citrate buffer and pH 7.4 PBS, without
additional DTT, to demonstrate that diffusion out of the dialysis cassette is possible and to
establish a comparison for evaluating the performance of copolymers P22-P23. As shown
in Figure 3.10A, free TMZ diffused through the cassette within 2 h, with approximately
75% and 100% of maximum TMZ release achieved at pH 7.4 and pH 4.5, respectively.
Block polyMPC-TMZ conjugates have been demonstrated to encapsulate free TMZ at
higher concentrations than comparable amphiphilic copolymers (i.e., polyMPC-butyl
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Figure 3.10: Drug release profiles in pH 4.5 citrate buffer of pH 7.4 PBS. (A) % of
Maximum TMZ or AIC release of free TMZ and polyMPC-TMZ/TMZ at pH 7.4. (B) %
of Maximum TMZ release of P22 and P23 at pH 4.5 with and without 3 mM DTT, with
free polyMPC and polyMPC-TMZ/TMZ for reference. (C) % of Maximum TMZ release
of P22 and P23 at pH 7.4 with and without 3 mM DTT, with free polyMPC and polyMPCTMZ/TMZ for reference. (D) % of Maximum AIC release of P22 and P23 at pH 7.4 with
3 mM DTT, with free polyMPC and polyMPC-TMZ/TMZ for reference.
methacrylate (BMA)).27 As such, TMZ encapsulated into polyMPC-TMZ (polyMPCTMZ/TMZ) was measured under the same testing conditions. Physically encapsulated
systems showed minimal difference from TMZ alone. However, while free TMZ achieved
approximately 95% of maximum AIC release, polyMPC-TMZ/TMZ only achieved 70%
of maximum AIC release in pH 7.4 PBS (Figure 3.10A). For copolymers P22-P23, the %
of maximum TMZ or AIC were calculated as the concentration of TMZ or AIC in the
aliquot relative to the maximum concentration of disulfide-linked TMZ or AIC in the
system. As before, this method does consider TMZ degradation over time at pH 7.4.
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Copolymers P22 and P23 showed no TMZ release at pH 4.5 or pH 7.4 without DTTenhanced buffer (Figure 3.10B and 3.10C, respectively), as expected. In pH 7.4 PBS + 3
mM DTT, P22 and P23 both reached approximately 30% of maximum TMZ and 80-90%
maximum of AIC released, with peak release achieved around 3 h (Figure 3.10D). Notably,
both systems still released viable TMZ up to 25 h. In pH 4.5 citrate buffer + 3 mM DTT,
P22-P23 reached approximately 30-40% of maximum TMZ release (Figure 3.10B).
The TMZ release profiles of P22-P23 in pH 7.4 PBS + 3 mM DTT were reevaluated
using an adjusted Amax, calculated as a function of time using the starting concentration of
disulfide-conjugated TMZ and the previously generated exponential decay curves (Figure
3.11). While the degradation profiles do not differentiate between disulfide-conjugated,
methacrylate-linked, or free TMZ, this nevertheless provides additional insight into the
efficiency of TMZ release from the polymer backbone at physiological pH.
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Figure 3.11: TMZ release profiles with adjusted Amax values for P22 (right) and P23 (left).
3.5 Incorporation of GEM into PolyMPC Conjugates
Combination chemotherapy is a promising alternative to traditional monotherapeutic administration, as the use of drugs with unique mechanisms of actions is
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expected to minimize or circumvent native chemoresistance. The incorporation of these
materials onto a single polymer backbone additionally overcomes the issue of disparate
pharmacokinetics, ensuring consistent co-drug delivery.30

Gemcitabine (GEM) was

selected as the second drug for polyMPC-TMZ conjugates, as it is not an alkylating agent
like TMZ and has been demonstrated to be a potent radiosensitizer in addition to being a
chemotherapeutic.20,21,26

GEM-MA

Scheme 3.1: Synthesis of GEM-methacrylate (GEM-MA).
Attempts at preparing gemcitabine (GEM)-thiol derivatives to mimic the disulfide
exchange post-polymerization strategy demonstrated with TMZ-containing conjugates
proved ineffectual: various carbodiimide and peptide coupling methodologies were lowyielding and produced several by-products, necessitating a different strategy for
incorporating GEM. The key monomer for this system, GEM-methacrylate (GEM-MA),
was prepared following a modified literature procedure.31 Esterification of the free base of
GEM was achieved through mild carbodiimide-mediated coupling with mono-2(methacryloyloxy)ethyl succinate (Scheme 3.1). GEM-MA was purified by aqueous
extraction followed by column chromatography, eluting with DCM/MeOH (15/1), and
isolated in yields of 20-30% as a white solid. Spectroscopic characterization of GEM-MA
confirmed successful coupling. In the 1H NMR spectrum, the resonance corresponding to
the amide moiety (δ = 11.07 ppm) was observed (Figure 3.12A). Additionally, the UV-vis
absorption spectrum of GEM and GEM-MA in water demonstrated a red shift from λ =
269 nm to λ = 297 nm (Figure 3.12B), due to the increased electronegativity of the amide
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Figure 3.12: (A) 1H NMR spectrum of GEM-MA with peak designations. (B)
Representative UV-vis spectra showing a 28 nm peak shift between GEM and GEM-MA,
indicative of amide formation.
compared to the free amine. GEM-MA demonstrated low solubility in the typical solvents
used for RAFT polymerization with zwitterions (e.g., water, methanol, and
trifluoroethanol), while its solubility in DMF and DMSO remained high (>50 mg/mL).
Various solvent systems for free radical and RAFT-mediated polymerizations were
screened for a polyGEM homopolymer (P24) and a polyMPC-GEM random copolymer
targeted 25 mole % GEM incorporation (P25) to determine ideal reaction conditions, as
summarized in Table 3.3. The RAFT co-polymerization of MPC and GEM-MA was
initially attempted in a trifluoroethanol (TFE)/dimethylformamide (DMF) solvent mixture

Figure 3.13: Attempted RAFT polymerization of MPC with GEM-MA to give polyMPCGEM random copolymers (P25), using dithiobenzonate CTA 1.
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to ensure homogeneity of both monomers (Figure 3.13). Such a solvent system would
likewise preserve the TMZ structure in later polymerizations, unlike methanol which has
been demonstrated to rapidly degrade the drug.32 However, monomer conversion was low
(< 10%) despite long reaction times upwards of 16 h. While the free radical polymerization
of GEM-MA using ACVA as the radical initiator produced a homopolymer of polyGEM
within hours, both free radical polymerization and RAFT-mediated polymerization
(utilizing a dithiobenzoate as the CTA; CTA 1) were unsuccessful for P24 and P25
copolymers.
Table 3.3: Polymerization conditions for polyGEM (P24) and random polyMPC-GEM
(P25).
Polymer

Conditions

Solvent

[M]

CTA

P24

free radical

DMF

0.5

-

P25

free radical

TFE/DMF

0.5

-

P24

RAFT

DMF

1.0

CTA 1

P25

RAFT

TFE/DMF

0.5

CTA 1

P25

RAFT

TFE/DMF

1.0

CTA 1

P24

RAFT

DMF

0.5

CTA 2

P25

RAFT

MeOH

0.5

CTA 2

P25

RAFT

MeOH

0.5

CTA 2

P25

RAFT

MeOH

1.0

CTA 2

Switching the CTA to 2-cyano-2-propyl dodecyl trithiocarbonate (CTA 2) allowed
for the successful preparation of P24 by RAFT polymerization. Similarly, the use of CTA
2 allowed for the preparation of polyMPC-GEM P25, particularly when the solvent system
was switched to methanol. While such conditions would be unsuitable for direct
incorporations of TMZ-MA, a post-polymerization strategy utilizing PDS-methacrylate
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and disulfide exchange with TMZ-thiol would preserve the drug structures and allow for
the preparation of multi-drug conjugates.
Given this insight, polyMPC-GEM prodrugs with random (P25-P27) and block
(P29-P32) copolymer architectures were prepared by RAFT polymerization in MeOH
utilizing CTA 2, as shown in Figure 3.14. Random copolymers were prepared by the copolymerization of MPC with GEM-MA at 70 °C, using ACVA as the radical initiator.
Polymerizations were quenched at high monomer conversion (>85%), as quantified by 1H
NMR, by opening to air. Crude polymers were purified by precipitation into THF, followed
(A)

P25-P27
(B)

P24

P28-P31
Figure 3.14: Synthesis of polyMPC-GEM copolymers with random (A) and block (B)
copolymer architectures by RAFT polymerization of GEM-methacrylate (GEM-MA).
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by dialysis against RO water to remove unreacted monomers. Lyophilization gave P25P27 as light yellow solids in 50-60% yields. A polyMPC macro-CTA (P28), for use in
synthesizing polyMPC-GEM block copolymers P29-P32, was prepared by the
homopolymerization of MPC in methanol at 70 °C, utilizing CTA 2 and ACVA. The
polymerization was quenched at <90% monomer conversion to ensure retention of living
chain ends. GPC eluting in water, using poly(ethylene oxide) (PEO) standards, gave a low
dispersity (Đ) value of 1.39. Block copolymers P29-P32 were prepared by chain extension
of P28 with GEM-MA in MeOH at 70 °C, using ACVA as the radical initiator. For both
the random and block polyMPC-GEM conjugates, an appropriate solvent system for 1H
NMR was not found: methanol (MeOD)/DMSO combinations were too cloudy for
analysis, while pure MeOD does not properly solubilize GEM moieties for
characterization. As such, GEM incorporation was estimated using UV-vis spectroscopy.
Polymer characterization is summarized in Table 3.4.
Table 3.4: GEM Drug Loading and Molecular Weight Characterization of Copolymers
P25-P32.
GEM
Polymer
Feed XMPC
Feed XGEM
incorporationa
Đb
(%)
P25

75

25

13-14

1.39

P26

65

35

8

1.50

P27

50

50

11-12

1.41

P28

67

-

-

1.39

P29

85

15

15

3.09

P30

75

25

31-33

3.53

P31

65

35

22-24

3.60

P32

50

50

-c

-c

a

From UV-vis spectroscopy; bFrom aqueous GPC (PEO standards); cPolymer was not
isolated
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3.6 Conclusions
In summary, multiple routes to prepare polymer-drug conjugates intended to
overcome native chemoresistance were explored. While the preparation of disulfiramcontaining copolymers proved ineffective due to the instability of pendent TMZ groups,
polyMPC-TMZ conjugates with two methods of TMZ incorporation—disulfide and
methacrylate linkers—were synthesized in random and block architectures. These
copolymers demonstrated hydrolytic stability and drug release dependent on the
concentration of reducing agent, such as DTT. Finally, preliminary attempts at synthesizing
polyMPC

conjugates

containing

gemcitabine,

a

potent

radiosensitizer

and

chemotherapeutic, were described. These materials are expected to have utility both as
injectable conjugates and as components of implantable hydrogel systems, as described in
Chapter 4.
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CHAPTER 4
INCORPORATING TEMOZOLOMIDE INTO SOFT HYDROGEL PELLETS

4.1 Introduction
Glioblastoma is a highly aggressive brain cancer that represents the majority of
central nervous system (CNS) cancer diagnoses in the United States, affecting more than
100,000 patients annually.1 Despite extensive treatment—a combination of surgical
resection, radiotherapy, and chemotherapy—average survival times remain low at 12-15
months following diagnosis.2,3 Moreover, the vast majority of patients experience local
tumor recurrence within 2 cm of the original tumor site due to the presence of infiltrative
cells in surrounding healthy tissue.4–6 The blood-brain barrier (BBB) presents an additional
challenge to successful treatment, as it prevents most chemotherapeutics from entering the
brain. Clinically, drugs for glioblastoma treatment are typically small, lipophilic alkylating
agents, such as carmustine (BCNU), lomustine, and procarbazine. The first-line
chemotherapeutic, temozolomide (TMZ), is a bis(imidazotetrazine) heterocycle that
releases an alkylating methyldiazonium cation upon degradation at physiological pH. DNA
alkylation, occurring primarily at the O6 positions of guanine residues, leads to DNA
mismatch errors and subsequent cell death.7,8 However, while TMZ is potent against
glioblastoma, it suffers from poor aqueous solubility, off-target toxicity, and poor
pharmacokinetics, with a plasma half-life (t1/2) of less than 2 h.7,9–12
The difficulties associated with intravenous administration of chemotherapeutics
may be neatly avoided with the application of local delivery devices. Such materials ensure
high drug concentration at the affected site and thereby minimize systemic toxicity.
Moreover, judicious selection of the monomer or polymer components allows for the
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preparation of materials having a wide range of mechanical properties, drug release
kinetics, and degradation pathways. To date, there exist few examples of such devices for
glioblastoma treatment, and Gliadel® wafers remain the only materials with FDA
approval. These pellets are composed of a 1,3-bis(p-carboxyphenoxy)propane (CPP) and
sebacic acid (SA) copolymer matrix, into which carmustine is homogeneously
incorporated. Following surgical removal of the tumor, up to eight Gliadel® wafers are
applied to the lining of the resection cavity. Carmustine releases continuously over the
course of five days, and the wafers are expected to degrade after 6-8 weeks.13–15 Although
Gliadel® wafers improved the overall survival of patients with primary and recurrent
malignant gliomas,16,17 their clinical use included severe side effects, including brain
edemas, seizures, and intracranial bleeding.18–20 Potential alternatives to Gliadel® wafers
include drug-loaded poly(lactic acid-glycolic acid) (PLGA) wafers,21 3D-printed flexible
meshes,22,23 photopolymerizable hydrogels,24 and acetylated dextran scaffolds.4 While
these polymer-drug platforms have demonstrated efficacy in murine in vivo glioblastoma
models, further advances in local delivery of therapeutics are needed to ensure postoperative patient safety.25
As described in Chapter 1, polymer-TMZ conjugates were prepared using a
versatile TMZ-methacrylate monomer and 2-methacryloyloxyethyl phosphorylcholine
(MPC), a zwitterionic monomer known to make polymers displaying excellent
biocompatibility, water solubility, and resistance to protein and bacterial adsorption. Direct
incorporation of TMZ into polymeric structures as pendent moieties significantly enhanced
the chemical stability of TMZ in aqueous environments, while maintaining against
chemosensitive (U87MG) and chemoresistant (T98G) human cell lines.11,12 Using a
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similarly polymerizable TMZ strategy, this chapter focuses on the preparation of soft
hydrogels and shelf-stable polymer pellets using polyMPC-TMZ conjugates through
photo-initiated polymerization with biocompatible crosslinkers that are designed as
potential implants for use in glioblastoma treatment. Key evaluations of these materials
were conducted by Elizabeth Stubbs (rheology and dynamic mechanical analysis),
Alexandria Triozzi and Dr. Rita Das Mahapatra (cell viability; biocompatibility), and Ning
Hsuan-Tseng (cell viability).

4.2 Experimental Methods to Integrate TMZ Monomers into Hydrogels
The convenient polymerizable groups of TMZ-methacrylate (TMZ-MA) and
disulfide-containing TMZ-methacrylamide (TMZ-Ma) allowed direct incorporation of
TMZ into polymers, as described in Chapters 2 and 3. These monomers are similarly wellsuited for crosslinking chemistries to produce hydrogels containing covalently bound
TMZ. To this end, TMZ-loaded hydrogels were prepared by the UV-mediated crosslinking
of TMZ-MA or TMZ-Ma with 2-methacryloyloxyethyl phosphorylcholine (MPC) and a
poly(ethylene glycol) dimethacrylate (PEGDMA) crosslinker (Mn ~ 1 kDa), targeting 15
weight % MPC, 5-10 weight % crosslinker, and 5 weight % (relative to the total solution
volume) of TMZ-MA or TMZ-Ma (Figure 4.1). MPC and PEG were selected for their
well-characterized biocompatibility and antifouling behavior, and PC-PEG hydrogels have
been previously reported as a class of mechanically tunable materials for cell-contact
applications.26 While similar hydrogel systems can be formed from aqueous solutions of
the monomers and crosslinker, the low solubility of TMZ-containing monomers in water
necessitated the use of 2,2,2,-trifluoroethanol (TFE), a solvent shown to preserve the
structural integrity of TMZ in controlled free radical polymerizations.11,12 Hydrogels were
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formed by irradiation of the TFE solutions using 365 nm light in the presence of Irgacure
2959 (1 weight %) as the radical photoinitiator. Following irradiation, however, the
hydrogels appeared white and opaque, suggesting heterogeneous incorporation of the TMZ
monomer into the structure. Additionally, despite 30 minutes of irradiation time, the
hydrogels were mechanically weak and broke apart easily.

MPC
PEGDMA (Mn ~ 1kDa)
Irgacure 2959, TFE

TMZ-methacrylate
(TMZ-MA)

λ = 365 nm
Irradiation time:
30 min

or

TMZ-methacrylamide
(TMZ-Ma)

Sample

MPC
(weight %)

TMZ-MA
(weight %)

TMZ-Ma
(weight %)

PEGDMA
(weight %)

C1

15

5

-

5

C2

15

-

5

5

C3

15

5

-

10

C4

15

-

5

10

C1

C2

C3

C4

Figure 4.1: Top: Preparation of TMZ-loaded hydrogels using TMZ-methacrylate (TMZMA) or TMZ-methacrylamide (TMZ-Ma) by UV-initiated crosslinking. Bottom: table
summarizing feed MPC, TMZ-MA, or TMZ-Ma, and PEGDMA ratios, beside images of
hydrogels taken immediately after irradiation.
4.3 Preparation of TMZ-loaded PC-PEG Hydrogel Pellets
As an alternative to systems directly incorporating TMZ-containing monomers,
polyMPC-TMZ conjugates were employed in a lyophilization method to produce drugloaded gels in the form of pellets, which can be stored for weeks-to-months prior to surgery
under ambient conditions without drug degradation. Figure 4.2 illustrates the two
encapsulation/gelation strategies described in this section: physical encapsulation of (1)
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random copolymers into PC-PEG hydrogel matrices and (2) block copolymers with
encapsulated additional TMZ into PC-PEG hydrogel matrices.

Figure 4.2: Schematic of TMZ-containing hydrogel structures: (A) block polyMPC-TMZ
(25 mole % TMZ) with encapsulated free TMZ and (B) random polyMPC-TMZ (25 or 50
mole% TMZ).
Random (P2 and P4) and block (P7) copolymers of polyMPC-TMZ were prepared
by reversible addition-fragmentation chain-transfer (RAFT) polymerization, using
methods

similar

to

those

reported

previously

with

4-cyano-4-

(phenylcarbonothiolythio)pentanoic acid and a dithioester-terminated polyMPC macroCTA as the chain-transfer agent (CTA), respectively (Figure 4.3).11,12 TMZ incorporations
and polymer molecular weights were estimated by 1H NMR spectroscopy and GPC,
respectively, following purification by precipitation and dialysis. Random copolymers
were isolated with TMZ incorporations of 25-28 weight % (P2) and 48-51 weight % (P4)
and Mn values of 36-46 kDa. Block copolymers (P7) were isolated with TMZ
incorporations of 25-28 weight % and Mn values of 19-27 kDa. These copolymers were
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P7: 25 mole % TMZ

P2: 25 mole % TMZ
P4: 50 mole % TMZ

Figure 4.3: Structures of random (P2 and P4) and block (P7) polyMPC-TMZ copolymers
and associated mole % TMZ incorporations.
selected for their excellent water solubility and proven ability to significantly increase the
hydrolytic stability of pendent TMZ moieties under physiological conditions. Free TMZ
has a reported blood plasma half-life (t1/2) of 1.8 h, while random and block polyMPCTMZ copolymers demonstrated t1/2 values of 2-3 and 18-19 h, respectively, under
physiological buffer conditions (i.e., pH 7.4 phosphate-buffered saline, 37 °C).9,12
Moreover, polyMPC-TMZ block copolymers demonstrated increased free TMZ
encapsulation (5 mg/mL TMZ) relative to other amphiphilic copolymers (e.g., poly(MPCb-butyl methacrylate)) with comparable hydrophobic content.
Critically important to these materials is for TMZ to maintain its structural integrity
during crosslinking. The selection of curing conditions and radical photoinitiator depends
on several factors and their potential associated complications, such as solution pH,
initiation wavelength, and photoinitiator efficiency at the employed wavelength. While
hydrogel formation may be performed in acidic conditions (e.g., utilizing aqueous HCl) to
preserve the TMZ structure, as is done for polymer purification, residual acid in the
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hydrogel matrix would be cytotoxic; moreover, dialysis to return the hydrogel to a neutral
pH state occurs on a timescale unsuitable to TMZ preservation (i.e., hours to days) and
would result in the release of physically encapsulated TMZ, necessitating the use of neutral
solvent for hydrogel formation. As the hydrogel curing must take place at approximately
pH 7.4, photoinitiation must be rapid and effective to minimize TMZ exposure to this
environment. Many radical photoinitiators have appreciable water solubility, but the
absorption characteristics of TMZ further complicate this selection, as the absorption peaks
of useful photoinitiators (e.g., Irgacure 2959) fall below λ = 300 nm and into the range of
TMZ absorption. The molar extinction coefficients of these photoinitiators at wavelengths
not absorbed by TMZ (λ >365 nm) are low and prevent rapid crosslinking, as demonstrated
with the TMZ monomer systems above, and thereby endanger the TMZ structure.
Additionally, longer irradiations times have been associated with decreased cell viability
in other PEGDMA-based hydrogel systems.27 Water-soluble azo-initiators, such as 2,2’azobis[2-(2-imidazolin-2-yl)propane]

(VA-044)

and

2,2’-azobis[2-methyl-n-(2-

hydroxyethyl) propionamide] (VA-086), are thus attractive alternatives since their
absorption peaks are between λ = 360-400 nm. While the higher molar extinction
coefficients of these initiators at λ = 365 nm will minimize the time TMZ spends in water
(e.g., reducing hydrolysis), this increased generation of radicals is also associated with
decreased

cell

viability,

as

demonstrated

with

lithium

phenyl-2,4,6-

trimethylbenzoylphosphinate (LAP) compared to Irgacure 2959.27 Nevertheless, aqueous
solutions of 15 weight % TMZ and 1 weight % VA-044 in pH 7.4 PBS, when irradiated
with 365 nm, showed no TMZ degradation by UV-vis spectroscopy. As such, with this
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insight, pH 7.4 PBS was selected as the solvent and VA-044 as the radical photoinitiator
for the hydrogel systems.
PC-PEG hydrogels containing random polyMPC-TMZ copolymers (H1-H2) were
prepared using hydrogel precursor solutions containing MPC (15 weight %), PEGDMA
(25 weight %), VA-044 (1.2 weight %), and solutions of polyMPC-TMZ random
copolymers P2 or P4 in aqueous 0.1 M HCl at a concentration of 40 mg/mL. Hydrogel
precursor solutions were irradiated with 365 nm light for six minutes in untreated 24-well
cell plates, then lyophilized to yield orange/pink cylindrical pellets (Figure 4.4A). This
color is attributed to the dithioester chain-ends of polyMPC-TMZ. PC-PEG hydrogels
containing block polyMPC-TMZ copolymers (H3-H6) were prepared under similar
conditions, utilizing a 5 mg/mL solution of the block copolymer (which has a noticeably

(A)

H2

(B)

H3

H6

Figure 4.4: Lyophilized PC-PEG hydrogels containing either random (A) or block (B)
polyMPC-TMZ copolymers, with free TMZ encapsulated into the latter. Weight
percentages shown are PEGDMA amounts
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lower aqueous solubility than comparable random copolymers). The TMZ loading of the
hydrogels was thus supplemented by the encapsulation of free TMZ in polyMPC-TMZ
block copolymer aggregates, giving TMZ concentrations of >6 mg/mL per hydrogel.
Additionally, the lower concentrations of polymer utilized allowed for examination of a
greater range of PEGDMA concentrations (12-50 weight %). Following curing and
lyophilization, PC-PEG hydrogels containing polyMPC-TMZ block copolymers with
encapsulated TMZ (hereafter referred to as polyMPC-TMZ/TMZ) were obtained as white
pellets (Figure 4.4B). Notably, pellets prepared with 12 weight % PEGDMA were
inconsistent in size and shape following lyophilization, while 25-50 weight % PEGDMAcontaining pellets were consistently cylindrical. As summarized in Table 4.1, the diameters
and heights of pellets ranged between 12-14 mm and 4-6 mm, respectively. Additionally,
TMZ incorporations (weight %) of 1.8-3.1 were achieved.
Table 4.1: Characterization of lyophilized pellets with physically incorporated TMZ.
Weight % of TMZ in the pellet was calculated using the final mass in mg of the pellets
after lyophilized compared to the feed mass in mg of TMZ.
mole %
weight %
weight %
Sample
TMZ in
TMZ in
d (mm)a
h (mm)a
PEGDMA
polymer
hydrogel
H1

25

25-28

2.1 ± 0.1

-b

-b

H2

25

48-51

2.0

-b

-b

H3

12

25-28

3.1 ± 0.1

-b

-b

H4

25

25-28

2.7 ± 0.3

12.2 ± 0.5

4.63 ± 0.3

H5

35

25-28

2.4 ± 0.1

13.9 ± 0.3

6.03 ± 0.1

H6

50

25-28

1.8

13.7 ± 0.3

5.08 ± 0.1

a

b

Dimensions calculated using ImageJ (n = 6 for H4; n = 3 for H5-H6); wafers irregularly
shaped.
The volume and mass swelling ratios of the hydrogel pellets following
lyophilization were examined by soaking the gels in PBS to equilibrate the swollen state.
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After three days, excess water was removed, and the weight of the swollen pellets was
compared to that of the dried hydrogels. While pellets H1-H3 were too inconsistent in
shape for dimension measurements following lyophilization, during swelling they regained
their cylindrical shape (Figure 4.5A). As expected, the mass swelling ratio of the hydrogels
was inversely dependent on crosslinker concentration. The volume swelling ratio was
similarly calculated for gels H4-H6; however, pellet H5, prepared with 35 weight %
PEGDMA, did not follow the expected inverse trend, as shown in Figure 4.5B. The average
mesh sizes (ξ) of the pellets across a range of PEGDMA incorporations (12, 25, 35, 50
weight %) ranged from 5.1-6.2 nm (Figure 4.5C), consistent with reported values in other
common hydrogels containing PEGDMA (ξ = 0.95-5.3 nm) or PEG-diacrylate (ξ = 1.4-7
nm).26,28
H2

H3

(B)

H6

9

mass
volume

8
7

swollen

Swelling Ratio

dry

(A)

6
5
4
3
2
1
0
H3

(C)

PEGDMA
(weight %)

ξ (nm)

12

5.1

25

5.6

35

5.8

50

6.2

H4

H5

H6

ξ

Figure 4.5: Swelling characterization of H1-H6: (A) Representative photographs of
hydrogels in the dry and swollen states for H2, H3, and H6. (B) Mass and volume swelling
ratios calculated for each hydrogel after swelling in pH 7.4 PBS for 72 h (n = 3; error
represents standard deviation). (C) Average mesh size (ξ) calculated for each hydrogel (n
= 3; error represents standard deviation).
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For most patients, glioblastoma tumors recur within weeks of surgical resection.2
The timing of drug release from local delivery devices is critical to suppressing tumor
regrowth. The hydrolytic instability of TMZ in physiological conditions necessitates
additional screening measures for complete characterization of wafer release kinetics. TMZ
release from pellets was evaluated by UV-vis spectroscopy, specifically monitoring the
absorption peaks corresponding to the urea moiety of TMZ (λ = 328-330 nm) and the
carboxyl group of the AIC by-product (λ ~ 267 nm) over time, in both pH 4.5 citrate buffer
and pH 7.4 phosphate-buffered saline (PBS). Pellets H1-H6 were prepared from 1 mL of
hydrogel precursor solution in 24-well untreated cell plates and lyophilized following
irradiation. Lyophilized pellets were added to reservoirs of pH 4.5 citrate buffer or pH 7.4
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Figure 4.6: Release profiles for pellets H1-H6 in pH 7.4 PBS (left) and pH 4.5 citrate buffer
(right), as measured by % of maximum TMZ and % of maximum AIC in the wafers (n =
3; error represents standard deviation). Hydrogels were incubated at 37 °C.
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PBS (225 mL) and incubated at 37 °C. At selected time points, aliquots (1 mL) were
removed from the surrounding medium and replaced with fresh buffer. The concentration
of TMZ or AIC was determined by comparison of the UV-vis spectroscopy absorption
peaks to previously generated calibration curves. As shown in Figure 4.6A, pellets H1-H2
showed an initial burst of TMZ release over 3 h, followed by a slower TMZ degradation
over the following 25-28 h. The % of maximum TMZ released (i.e., the TMZ in the
medium compared to the total TMZ initially in the wafer, assuming no degradation)
reached only ~10% release for H1, with H2 exhibiting slightly lower release. The
comparative % of maximum AIC curves (calculated assuming complete degradation of the
TMZ incorporation into the pellets) showed similar plateaus. Pellets H3-H6 exhibited a
similar initial burst release within the first 3 h, but these samples achieved much greater
TMZ release of 20-45% of the maximum TMZ in the wafer (Figure 4.6B). However, the
slow degradation period was comparatively shorter (e.g., 5-8 h). Maximum TMZ release
(%) was dependent on crosslinker concentration: pellets containing 12 weight % PEGDMA
achieved ~45% TMZ release, while pellets containing 50 weight % PEGDMA only
reached ~20% TMZ release and experienced faster TMZ degradation. Similarly, H3 pellets
exhibited higher AIC concentrations in the media, plateauing around ~60% AIC, while H6
pellets only reached ~50% of the maximum AIC in the media. To determine TMZ release
without TMZ degradation, pellets were incubated in pH 4.5 citrate buffer at 37 °C (Figure
4.6C-D). As before, pellets with random polyMPC-TMZ exhibited maximum TMZ release
of approximately 10%, while pellets H3-H6 achieved 45-60% maximum TMZ release.
The long-term stability of TMZ incorporated into pellets was examined by allowing
a pellet containing 25 weight % PEGDMA and loaded with polyMPC-TMZ/TMZ to stand
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for several months in ambient conditions. After 8 months, the pellet (H4a) was incubated
in pH 7.4 PBS at 37 °C, and TMZ and AIC release was evaluated (Figure 4.7). Relative to
a pellet prepared and stored for minimal time (< 1 week) at -20 °C (typical conditions to
preserve TMZ moieties on polyMPC-TMZ conjugates), H4a demonstrated comparable
TMZ and AIC release profiles, indicating excellent shelf-stability of pellets produced by
this protocol.

Figure 4.7: Release profiles for lyophilized wafers containing polyMPC-TMZ/TMZ and
25 weight % PEGDMA (H4 and H4, aged), as measured by % of maximum TMZ and %
of maximum AIC in the wafers (n = 3 for H4; error represents standard deviation).
Hydrogels were incubated in pH 7.4 PBS at 37 °C.
The soft nature of brain tissue—with reported moduli around 1 kPa under shear
deformation29,30—necessitates implantable devices to have comparable mechanical
properties to avoid tissue injury, as seen with stiff wafers like Gliadel®.30 Pellets were
characterized by rheology using oscillatory frequency sweeps and by dynamic mechanical
analysis (DMA). For these assessments, the hydrogels were prepared without loaded TMZ,
as physically encapsulated TMZ would release during the course of swelling. PC-PEG
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hydrogels were prepared over a range of PEGDMA concentrations (12, 25, 35, and 50
weight %) in silicone molds and swelled in water for 72 h. Oscillatory frequency sweeps
were performed from 0.1 to 10 s-1 at 5% strain at room temperature (19 °C) for each
crosslinker concentration. The shear storage modulus (G’) is expected to scale with
crosslinker concentration (i.e., increased PEGDMA content increases the storage
modulus), but the 35 weight % PEGDMA gel did not follow this trend, as was seen in the
volume swelling ratio calculations. However, the moduli of the gels overall were similar
or slightly greater than the reported modulus of brain tissue under shear deformation,
indicating good potential mechanical compatibility. Dynamic mechanical analysis (DMA)
was performed on PC-PEG hydrogels over a range of PEGDMA concentrations (12, 25,
35, and 50 weight %), prepared in untreated 24-well cell plates and swollen for 72 h in
water. Samples were compressed at a constant displacement rate of 2 μm/s at room
temperature (22 °C), and the modulus was calculated from the slope of the stress-strain
curve in the range of 0-5% strain. As shown in Figure 4.8, the Young’s moduli (E) obtained
by DMA was higher than those determined by shear rheology (G), ranging between 2.96.4 kPa, as expected (E ~ 2G). As with results obtained by oscillatory frequency sweeps,
these values further suggest good mechanical compatibility with brain tissue.
(A)

(B)
PEGDMA
(wt %)

Young’s
modulus
(kPa)

12

2.9

25

5.7

35

6.1

50

6.4

Figure 4.8: Oscillatory frequency sweep (A) and dynamic mechanical analysis (DMA) (B)
of PC-PEG hydrogels with 12, 25, 35, and 50 weight % PEGDMA incorporation. Young’s
modulus (E) from DMA shown in inset table.
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4.4 Preliminary In Vitro Evaluations
Working with Alexandria Triozzi, the antitumor activity of TMZ-containing PCPEG pellets was investigated in a TMZ-sensitive human glioblastoma cell line (i.e.,
U87MG). Lyophilized pellets with 12, 35, or 50 weight % PEGDMA were prepared in
untreated 96-well cell plates with and without physically loaded polyMPC-TMZ/TMZ.
The pellets were incubated on top of seeded U87MG cells for 48 h, with untreated U87MG
cells serving as a negative control. Cell viability was determined using a CellTiter-Glo®
assay to generate dose-response curves (Figure 4.9A). Notably, the pellets demonstrated
high cytotoxicity, regardless of TMZ content and PEGDMA concentration. Therefore, the
biocompatibility of the hydrogel matrix materials was then assessed. U87MG cells were
exposed to 0.1, 2.5, and 5 mg/mL aqueous solutions of PEGDMA, MPC, polyMPC, and
VA-044 for 48 h, followed by cell viability measurements. Cells without added
components served as a negative control (Figure 4.9B). MPC has been previously
demonstrated to be well-tolerated at exceptionally high doses (800 mg/kg) in NOD SCID
mice without evidence of systemic toxicity (i.e., weight loss or behavioral changes),31 and
(B)

PEGDMA

MPC

polyMPC

VA-044

Normalized viability (%)

Normalized viability (%)

(A)

gel
U87MG

PEGDMA weight %

Reagent concentration (mg/mL)

Figure 4.9: (A) Cell viability of pellets H3, H5, and H6 (with and without loaded TMZ) in
U87MG glioblastoma cells, relative to cells incubated without pellets. (± indicates standard
deviation). (B) Cell viability of hydrogel components PEGDMA, MPC, polyMPC, and
VA-044 in U87MG glioblastoma cells (± indicates standard deviation).
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as expected it exhibited high biocompatibility and minimal cell death in U87MG cells.
However, both PEGDMA and VA-044 were noticeably toxic to U87MG cells,
demonstrating significant cytotoxicity at concentrations of 2.5 mg/mL and 0.1 mg/mL,
respectively.
The high cytotoxicity of VA-044 prompted an investigation into the effect of
radical photoinitiator on PC-PEG pellet production and biocompatibility by Dr. Rita Das
Mahapatra, in Professor Shelly Peyton’s laboratory at UMass Amherst. Pellets prepared
with 1.2 weight % VA-044 (H4 and H6) or Irgacure 2959 (H4I) were evaluated against
U87MG cells. The preparation conditions are summarized in Figure 4.10. Prior to testing,
pellets were washed by soaking in 24 h intervals of either: (1) four times with serum-free
media (SFM) or (2) twice with water, followed by twice with SFM. Unwashed pellets,
washed pellets, and aliquots from the washing cycles were incubated with U87MG cells
for 48 h, with untreated cells and media serving as negative controls. Cell viability was
determined by a CellTiter-Glo® assay and summarized in Figure 4.10A-D. In general,
pellets prepared using VA-044 were significantly more cytotoxic than those prepared using
Irgacure 2959, and media aliquots from Irgacure 2959 pellets were less toxic even at the
first wash. However, pellets made with Irgacure 2959 were still cytotoxic without
additional washing steps compared to control cells (Figure 4.10E). Additionally, pellets
made with Irgacure 2959 required longer irradiation times (12 minutes) compared to those
made with VA-044 (6 minutes) to completely crosslink and were noticeably less
mechanically robust during handling. As such, further attempts at preparing biocompatible
PC-PEG pellets investigated the effect of lower VA-044 concentration.
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Figure 4.10: Cell viability of pellets H4 prepared under various conditions, as summarized
in the inset table. Gels were tested against U87MG cells after washing with serum-free
media (SFM) four times (A) or water twice and SFM twice (B). Aliquots from washing
cycles were also tested against U87MG cells (C-D). Unwashed gels were tested against
U87MG cells to determine the effect of photoinitiator (E). (± indicates standard deviation;
n = 3).
4.5 Adjusting VA-044 Content in Hydrogel Pellets
PC-PEG hydrogels were prepared over a range of VA-044 concentrations (1.2, 0.1,
0.05, and 0.01 weight %) with MPC (15 weight %) and PEGDMA (25 weight %). Hydrogel
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precursor solutions were irradiated with 365 nm light for 6 minutes, then lyophilized to
yield white pellets. As shown in Figure 4.11A, hydrogels prepared with 0.1 and 0.05 weight
% VA-044 (H7 and H8, respectively) retained a roughly cylindrical shape, compared to
pellets made with 1.2 weight % VA-044, but lower photoinitiator concentrations resulted
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Figure 4.11: Characterization of gels prepared without loaded TMZ: (A) Representative
images of dry and swollen PC-PEG pellets prepared with 0.01 weight % to 1.2 weight %
VA-044. (B) Mesh sizes of H4, H7-H8. Grayed out bars indicate skewed data. (C) Mass
and volume swelling ratios of H4, H7-H8. (D) TMZ release in pH 4.5 citrate buffer of H4
and H7 prepared by 6 or 9 minutes of irradiation with 365 nm light. (E) Oscillatory
frequency sweep comparing H4 and H7 pellets.
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in mechanically weak structures (H9). The volume and mass swelling ratios, as well as the
average mesh sizes (ξ), of the pellets following lyophilization were examined by soaking
the gels in water until equilibrated and comparing the dry and swollen states. Hydrogels
prepared with 0.1 weight % VA-044 were comparable to those prepared with 1.2 weight
% VA-044 in terms of both swelling ratios and mesh sizes (Figure 4.11B-C). Hydrogels
H8-H9 exhibited some degree of curing following 6 minutes of irradiation time, but a
significant amount of residual precursor solution was observed on top of the hydrogels
following irradiation. This is reflected in the mesh sizes and swelling ratios (Figure 4.11BC), which are overestimated due to mass loss from unincorporated precursor material.
Additionally, these gels were difficult to handle and mechanically weak compared to gels
prepared with 1.2 or 0.1 weight % VA-044, indicating that these initiator concentrations
are unusable unless irradiated for longer times. The mechanical properties of gels with
lower VA-044 content were analyzed by rheology and dynamic mechanical analysis. While
the shear storage and loss moduli (G’, G”) were reduced in pellets H7, the Young’s
modulus as estimated by DMA was significantly increased from 25.2 kPa (H4) to 52.0 kPa
(H7) (Figure 4.11D). As demonstrated in other systems, decreasing the photoinitiator
concentration is expected to increase the kinetic chain length of the polymers, resulting in
an increased modulus.32 Pellets H7 demonstrated roughly equivalent TMZ release profiles
to H4 gels regardless of irradiation time (Figure 4.11E).
To investigate the effect of lowering the VA-044 content on cell viability, PC-PEG
pellets without incorporated TMZ were prepared with either 1.2 or 0.1 weight % VA-044
and 25 weight % PEGDMA. In collaboration with Ning-Hsuan Tseng (S. Peyton research
group, UMass Amherst), unwashed and washed (as described previously) pellets were
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incubated with HEK298A or U87MG cells for 48 or 72 h, with untreated cells serving as a
negative control. Cell viability was determined using a CellTiter-Glo® assay to generate
dose-response curves (Figure 4.13). H4 and H7 pellets exhibited high cytotoxicity in both
cell lines without washing and biocompatibility upon washing, indicating that even very
low amounts of residual photoinitiator, or fragmented products of the polymerization
process, are deleterious to live cells.
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4.6 Circumventing PC-PEG Cytotoxicity
While PC-PEG gels of varying VA-044 content are biocompatible upon washing
cycles with water and/or serum-free media, the presence of physically encapsulated TMZ
and polyMPC-TMZ precludes any washing steps prior to use, as this would result in TMZ
burst release and degradation. Therefore, an alternative route to TMZ-loaded hydrogels
was undertaken as follows: drug-free PC-PEG pellets are washed, removing any residual
cytotoxic compounds, and following lyophilization drug is loaded into the matrices by
swelling in concentrated aqueous solutions of the drug. In doing so, the system takes
advantage of the enhanced water solubility of polyMPC-TMZ conjugates over free drug
alone and the increased hydrolytic stability of the polymers, which can allow for uptake
with minimal TMZ degradation if performed on a shorter timescale. To demonstrate the
uptake efficiency of these materials, blank H7 pellets were prepared in untreated 96-well
cell plates and lyophilized. The pellets were then submerged in 330 μL of a 40 mg/mL
solution of polymer P1 in pH 7.4 PBS. At predetermined intervals (10, 20, 30, or 60
minutes), the polymer solutions were decanted, and the swollen hydrogels (H11, H12,
H13, and H14, respectively) were placed into reservoirs of pH 4.5 citrate buffer (20 mL)
to be incubated at 37 C. Regardless of soaking time, each pellet absorbed ~120 μL of
polymer solution. At selected time points, aliquots (100 μL) were removed from the
external medium, and the concentration of TMZ was determined by UV-vis spectroscopy.
The % of maximum TMZ was calculated relative to the theoretical TMZ uptake (120 μL),
as shown in Figure 4.13A. Notably, the % of maximum TMZ released was higher than that
demonstrated in a pellet prepared with polyMPC-TMZ incorporated during curing (H15)
at around 30% TMZ released. The uptake and release of polyMPC-TMZ/TMZ (overall
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TMZ concentration of 6.35 mg/mL, as with gels H3-H6) was similar to that demonstrated
by hydrogels H16-H19 (Figure 4.13B). Unlike gels H11-H14, gels H16-H19 exhibited
around 60 % of maximum TMZ release, comparable to H4.
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Figure 4.13: Release experiments following uptake of random polyMPC-TMZ (A) and
polyMPC-TMZ/TMZ (B) in pH 4.5 citrate buffer.
H4 and H7 pellets without TMZ were washed with serum-free media over a range
of washing cycles (4 x 6 h, 8 x 6 h, and 4 x 12 h) to elucidate the minimum required time
to mitigate cytotoxicity (Figure 4.14A). Regardless of VA-044 incorporation, each
washing procedure was sufficient to remove cytotoxic components embedded in the
hydrogel matrix, demonstrating that longer 24 h cycles were not needed for further cell
studies. With this information, a preliminary cell viability study was performed to assess
the uptake/release procedure. H7 pellets were prepared, washed with SFM (4 x 6 h cycles),
and lyophilized. TMZ was loaded into some of the pellets by soaking in 330 μL of 40
mg/mL solution of P1 in pH 7.4 PBS for 10 minutes (yielding H11 pellets). The pellets,
both without (H7) and with (H11) TMZ, were incubated with U87MG cells for 72 h, with
untreated cells serving as a negative control. Cell viability was determined using a
CellTiter-Glo® assay. As shown in Figure 4.14B, the gels with P1 demonstrated no
significant difference in cytotoxicity compared to TMZ-free gels. Nevertheless, this uptake
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and release strategy presents a promising alternative to PC-PEG gels with TMZ
incorporated during the crosslinking stage, and further studies on the cytotoxicity of
uptake/release pellets need to be performed.
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Figure 4.14: Cell viability of pellets against U87MG cells: (A) H4 (1.2 weight % VA-044,
no TMZ) and H7 (0.1 weight % VA-044, no TMZ). Washing cycles consisted of 6 or 12 h
cycles of serum-free media (SFM) for 1 or 2 days. (± indicates standard deviation). (B) H7
(0.1 weight % VA-044, no TMZ) and H11 (0.1 weight % VA-044, loaded with polyMPCTMZ). Gels were washed (four 6 h cycles) prior to testing or loading with TMZ. (±
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4.7 Conclusions
In summary, a novel platform of TMZ-loaded hydrogels using PC-PEG was
prepared over a range of PEGDMA concentrations. The physical loading of TMZ, through
polyMPC-TMZ conjugates with and without encapsulated native TMZ, allowed for the
formation of hydrogels with a range of swelling and mechanical properties, as well as TMZ
release profiles in different physiological conditions. Moreover, the pellets proved stable
for months when stored at ambient conditions. While initial biocompatibility and cell
viability studies in healthy and glioblastoma cells exhibited cytotoxicity, alternative routes
to TMZ-loaded hydrogels which preserve the tunable release and mechanical properties
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were presented. The tunable properties of these pellets are promising for future in vitro and
in vivo applications.
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CHAPTER 5
SUMMARY AND OUTLOOK

5.1 Novel TMZ-containing Materials
While TMZ is the first-line chemotherapeutic for glioblastoma treatment, its use is
associated with numerous challenges, including low water solubility, poor drug stability,
and off-target toxicity. Compared to common chemotherapeutics used across a variety of
cancer types (e.g., doxorubicin), temozolomide remains a critical component of
glioblastoma treatment in part because of its ability to traverse the blood-brain barrier
(BBB). There is a tremendous need for developing TMZ-based systems which overcome
these challenges. This dissertation has highlighted the preparation of novel TMZcontaining materials, starting from a versatile TMZ-methacrylate (TMZ-MA), to address
this matter.
PolyMPC-TMZ conjugates, as described in Chapters 2 and 3, directly incorporate
TMZ into the polymer backbone through controlled free radical polymerization
methodologies. The use of post-polymerization chemistries further allows for the
preparation of polymer-drug materials which have redox-sensitive linkers between TMZ
and the polymer backbone. These conjugates have demonstrated architecture-dependent
aqueous solution assembly properties, drug stability in physiological conditions, and in
vitro cytotoxicity against chemosensitive and chemoresistant human glioblastoma cell
lines. Disulfide-containing conjugates additionally exhibited tunable drug stability, TMZ
release, and cytotoxicity dependent on the concentration of reducing agents (glutathione
and dithiothreitol). Moreover, this direct incorporation method allows for the addition of
co-monomers such as pyridyl disulfide methacrylate (PDS-MA) and gemcitabine
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methacrylate (GEM-MA) for versatile polymer-drug conjugates capable of addressing
native chemoresistance.
A significant expansion of these polymer-drug materials is presented in Chapter 4.
TMZ and TMZ-containing monomers, having minimal water solubility, cannot be
physically encapsulated into PC-PEG hydrogels prepared in aqueous solutions. However,
polyMPC-TMZ conjugates readily dissolve in water and can be incorporated to reach
between 2-10 weight % TMZ. These pellets demonstrated tunable drug release, enhanced
shelf stability, and mechanical properties closely matching those of brain tissue, suggesting
that their implantation would not result in tissue damage. The in vitro work presented here
furthermore provides a greater fundamental understanding of PC-PEG hydrogels.
Additional routes forward could include the use of polyMPC-TMZ copolymers with
functional co-monomers such as choline phosphate (CP) methacrylates. CP polymers offer
additional advantages over conventional polyMPC conjugates, as the introduction of
functional moieties does not come at the expense of decreased water solubility.

5.2 In Vivo and Clinical Evaluations of TMZ-loaded Materials
The work represented in this thesis represents a critical advancement for TMZcontaining materials for glioblastoma treatment, and this section will highlight the areas
which require further study. The incorporation of additional co-monomers into polyMPCTMZ structures is an obvious route forward. As discussed in Chapter 3, these co-monomers
stand to improve the overall efficacy of the injectable materials by providing substrates
(e.g., disulfiram) to overcome native enzymatic resistance, multiple drugs (e.g.,
gemcitabine or doxorubicin) for combinatorial chemotherapy, and targeting moieties for
traversing the blood-brain barrier (e.g., glutathione). The possible combinations of useful
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monomers are only limited by the polymerization reactions (and subsequent purifications)
used to access these materials, and as such there is much work to be done in this area.
A promising synthetic route includes the use of functional co-monomers, such as
choline phosphate (CP) methacrylates. CP polymers offer additional advantages over
conventional polyMPC-TMZ conjugates, as the introduction of functional moieties does
not come at the expense of decreased water solubility. Such polyMPC-MCP-TMZ
copolymers having alkene or alkyne functionality could be used in post-polymerization
conjugation reactions with thiol-containing compounds of interest which are not easily
converted into monomers, avoiding the need for direct incorporation through
polymerization reactions. These polyMPC-MCP-TMZ copolymers are additionally
promising for the development of TMZ-containing hydrogel materials. Crosslinking by
thiol-containing crosslinkers (e.g., PEG-thiol) would allow for the direct incorporation of
TMZ into the hydrogel matrix. It is anticipated that covalently bound TMZ would possess
different release and degradation rates compared to physically encapsulated TMZ, as was
seen with polyMPC-TMZ conjugates compared to polyMPC-TMZ/TMZ materials.
In general, there remains a wealth of experiments to be conducted building off of
the hydrogel work discussed here. The uptake of polyMPC-TMZ conjugates into washed
hydrogel pellets, as discussed in Chapter 4, is a promising development which stands to
circumvent the cytotoxicity problems seen in unwashed hydrogel materials while
maintaining the desired TMZ release profiles. While preliminary in vitro data suggested
minimal cytotoxicity, additional experiments on cell viability using TMZ uptake/release
pellets prepared under various conditions are needed. Moving forward, further research on
the effect of crosslinker length, multi-drug incorporation (e.g., doxorubicin), and TMZ
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uptake strategies on the mechanical properties, TMZ release/degradation, and pellet
cytotoxicity will help develop this hydrogel platform into a robust system with clinical
utility.
A critical component of biomedical research lies in the in vivo evaluation of
therapeutics. While in vitro work utilizing human glioblastoma cell lines provide some
insight into the viability and efficacy of polymer-drug injectable and implantable materials,
in vivo tumor models better mimic the aggressive and infiltrative nature of glioblastoma
tumor cells. Additionally, surgery remains a critical component of glioblastoma treatment,
and surgical resection impacts the peritumoral microenvironment and influences tumor
growth and recurrence.1,2 As such, complex animal models which involve tumor removal
are essential for evaluating systems intended for post-surgical implantation. Future
evaluations of polyMPC-TMZ systems would benefit from using both standard (e.g.,
subcutaneous flank or orthotopic tumors) and pre-clinical (i.e., orthotopic tumors which
are surgically removed after establishment) animal models. Ideally, both rat models and
larger animal models (e.g., dogs) would be utilized.
Finally, it is anticipated that the hydrogel materials described here will have
exceptional clinical utility, due to their highly tunable properties (i.e., drug loading/release,
swelling, and mechanical characteristics). For example, fluorescent imaging of the tumor
prior to surgical resection would give dimensional guidelines for hydrogel preparation.
Patients may have different needs for dosing schedules, and as such clinicians can select
from one of the many hydrogels described herein for one which closely matches the desired
drug release timeline. Overall, this thesis work represents a foundation for the future
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development of personalized TMZ-containing therapeutics which will be realized by
researchers, both within the Emrick research group and elsewhere.
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CHAPTER 6
EXPERIMENTAL SECTION

6.1 Materials
2-Methacryloyloxyethyl phosphorylcholine (MPC), 2-hydroxyethyl methacrylate
(HEMA), 4-(dimethylamino)pyridine (DMAP), sodium nitrite, dimethylsulfoxide
(DMSO), sodium trifluoroacetate, 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid
(CTA 1), 4,4’-azobis(4-cyanovaleric acid) (ACVA), cystamine dihydrochloride,
cysteamine, trityl chloride, methacryloyl chloride, reduced glutathione (GSH),
triisopropylsilane (TIPS), trifluoroacetic acid (TFA), Aldrithiol, mercaptoethanol,
dithiothreitol (DTT), pyridine, mono-2-(methacryloyloxyethyl)ethyl succinate, and 2cyano-2-propyl dodecyl trithiocarbonate (CTA 2) were purchased from Sigma-Aldrich.
Anhydrous diethyl ether, dichloromethane (DCM), ethyl acetate, hexanes, methanol
(MeOH), acetonitrile, concentrated sulfuric acid, tetrahydrofuran (THF), hydrochloric acid
(HCl), monobasic sodium phosphate (NaH2PO4), acetic acid, and sodium sulfate
anhydrous (Na2SO4) were purchased from Fisher Chemical. 2,2,2-Trifluoroethanol (TFE)
was

purchased

from

Oakwood

Products,

Inc.

Temozolomide

(TMZ),

1-(3-

dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), and gemcitabine
(GEM) were purchased from TCI America. Diethyldithiocarbamic acid sodium salt
trihydrate (SDT) was purchased from Santa Cruz Biotechnology. Poly(ethylene glycol)
1000 dimethacrylate was purchased from Polysciences, Inc. VA-044 was purchased from
Wako Pure Chemical Corporation. Deuterated solvents were purchased from Cambridge
Isotope Laboratories, Inc. Amicon® Ultra-15 regenerated cellulose centrifugal filters with
a nominal molecular weight cutoff of 10 kDa were purchased from Merck Millipore Ltd.
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Unless otherwise noted, all chemicals were used as received without further purification.
Inhibitor was removed from MPC prior to polymerizations following a previously
described procedure.1 Pyridyl disulfide-methacrylate (PDS-MA) was synthesized
following a literature procedure.2 Gemcitabine-methacrylate (GEM-MA) was synthesized
following a literature procedure.3 HEMA was purified by short-path vacuum distillation
using a Kugelrohr apparatus. Human glioblastoma (U87MG and T98G) cells and
HEK2983A cells were purchased from American Type Culture Collection (ATCC). Fetal
bovine serum (FBS) was purchased from Atlanta Biologicals. Gibco antibiotic-antimycotic
(100X) was purchased from Fisher Scientific. Cell viability was measured using CellTiterGlo® luminescent cell viability assays (Promega). Lysotracker Red® was purchased from
Life Technologies. Fluorescent 4’,6-diamidino-2-phenylindole (DAPI) stain was
purchased from Molecular Probes.

6.2 Instrumentation
1

H NMR (500 MHz), 13C NMR (125 MHz), and 31P NMR (202 MHz) spectra were

collected using a Bruker AscendTM 500 spectrometer equipped with a Prodigy cryoprobe.
High-resolution mass spectroscopy (HRMS) data were obtained using a JEOL-700
MStation spectrometer equipped with electron impact (EI) and fast atom bombardment
(FAB) sources. UV-vis absorption measurements were made on a Shimadzu UV-2600
spectrophotometer. Variable temperature UV-vis spectroscopy was performed using a
Quantum Northwest dual temperature-controlled cuvette holder and a TC 1 temperature
controller. Molecular weight and dispersity (Ð) values of polymers were estimated by gel
permeation chromatography (GPC) using TFE with 0.02 M sodium trifluoroacetate as
eluent. Narrow dispersity poly(methyl methacrylate) (PMMA) samples were employed to
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construct a calibration curve. GPC was operated at 1.0 mL/min and 40 °C with an Agilent
1200 system equipped with an isocratic pump, a degasser, an autosampler, one 50 x 8 mm2
Polymer Standards Service (PSS) PFG guard column, three 300 x 7.5 mm2 PSS PFG
analytical linear M columns with 7 µm particle size, and Agilent 1200 refractive index and
UV detectors. Molecular weight and dispersity (Ð) values of polymers P24-P32 were
estimated by aqueous gel permeation chromatography (GPC) in 0.1 M sodium nitrate and
0.02 weight % sodium azide buffer against poly(ethylene oxide) calibration standards. GPC
was operated at 1.0 mL/min with three Waters Ultrahydrogel columns (7.8 x 300 mm)
equipped with an RI detector. DLS was performed using a Malvern Zetasizer Nano ZS.
Cryo-TEM was performed on an FEI TecnaiT12 electron microscope using samples
prepared on 400 square mesh carbon-coated copper grids (Electron Microscopy Sciences).
Confocal microscopy was performed using a Nikon A1 resonant scanning confocal
microscope with structured illumination super resolution (A1R-SIMe). Rheological
characterization of hydrogels was performed using a TA Instruments Q2000 rheometer
equipped with a 25 mm aluminum plate. Compression tests on hydrogels were performed
using a TA Instruments Q800 dynamic mechanical analysis (DMA).

6.3 Methods
•

Synthesis of TMZ-carboxylic acid (TMZ-COOH)

TMZ-carboxylic acid (TMZ-COOH) was prepared following a previously described
procedure.4 In a round-bottom flask charged with a stir bar and fitted with an addition
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funnel, TMZ (2.29 g, 11.8 mmol) was dissolved in concentrated sulfuric acid (23.6 mL),
and the resulting yellow solution was cooled to 0 °C under nitrogen atmosphere. A solution
of sodium nitrite (2.51 g, 36.4 mmol) in water (23.6 mL) was added dropwise over 45
minutes, noting the evolution of a brown gas during addition. The mixture was allowed to
warm to room temperature while protected from light. After stirring for 17 hours, the
mixture was cooled to 0 °C and quenched with ice (61 g). Further stirring at 0 °C resulted
in precipitation of a fine white solid, which was isolated by vacuum filtration, washed with
cold water, and dried under vacuum to yield TMZ-COOH in 75% yield. 1H NMR (500
MHz, DMSO-d6, δ, ppm): 3.88 (s, 3H), 8.82 (s, 1H), 13.33 (br, 1H). 1C NMR (125 MHz,
DMSO-d6, δ, ppm): 36.32, 127.78, 129.09, 136.48, 139.10, 161.85. HRMS-EI (m/z): [M]+
calculated for C6H5N5O3: 195.0392, found: 195.0395.

•

Synthesis of TMZ-methacrylate (TMZ-MA)

In a round-bottom flask charged with a star bar, TMZ-COOH (592.5 mg, 3.05
mmol) was suspended in DCM (20 mL). HEMA (353 μL, 2.91 mmol) and catalytic DMAP
(36.0 mg, 0.29 mmol) were added to the suspension, followed by EDC (674 mg, 3.51
mmol); the mixture became homogeneous and red. After stirring under nitrogen at room
temperature for 14 hours, the mixture was filtered, and the filtrate was diluted with DCM
(30 mL) and washed with aqueous 0.1 M HCl (5 × 50 mL). The organic layer was dried
over sodium sulfate and concentrated by rotary evaporation. The resulting white solid was
dried under high vacuum, protected from light, to yield TMZ-MA in 71% yield. 1H NMR
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(500 MHz, DMSO-d6, δ, ppm): 1.87 (s, 3H), 3.88 (s, 3H), 4.43 (t, J = 5Hz, 2H), 4.62 (t, J
= 5Hz, 2H), 5.68 (s, 1H), 6.04 (s, 1H), 8.85 (s, 1H).

C NMR (125 MHz, DMSO-d6, δ,

13

ppm): 17.93, 36.40, 62.49, 62.51, 126.15, 126.20, 129.41, 135.60, 136.87, 138.93, 160.29,
166.41. HRMS-FAB (m/z): [M+H]+ calculated for C12H14N5O5: 308.0995, found:
308.0989.

•

General procedure for the synthesis of polyMPC-TMZ random copolymers (P1P4)

MPC and TMZ-MA were dissolved in TFE at a total monomer concentration of 1
M

in

a

20-mL

vial

charged

with

a

stir

bar.

ACVA

and

4-cyano-4-

(phenylcarbonothioylthio)pentanoic acid were added as radical initiator (I) and chaintransfer agent (CTA), respectively, targeting [monomer]0:[CTA]0:[I]0 of 68:5:1. The
mixture was purged with nitrogen gas at 0 °C for 15 minutes, then stirred at 70 °C to initiate
polymerization, judging monomer conversion by 1H NMR spectroscopy. At monomer
conversion >85%, the mixture was allowed to cool to room temperature then was quenched
by exposure to air. The crude reaction mixture was precipitated from TFE into THF (this
was repeated three times) to remove unreacted monomer, and the polymer was isolated by
centrifugation. The isolated polymer was dissolved in aqueous 0.1 M HCl (10 mL), added
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to a centrifugal filter with a nominal molecular weight cutoff of 10 kDa, and centrifuged
(4000 x g, 20 minutes, room temperature). The filtrate was discarded, and centrifugal
dialysis was repeated twice. The concentrated polymer was dissolved in 0.1 M HCl, and
lyophilization afforded polymers P1-P4 as pink solids. Incorporation of TMZ-MA into the
copolymer structure was estimated by 1H NMR spectroscopy by comparing relative signal
intensities at 8.46 ppm (C—H in TMZ) and 2.80-3.30 ppm (N—(CH3)3) in MPC.
Copolymer yields were 60-74%. 1H NMR (500 MHz, TFE-d3, δ): 0.08-1.09 (br, 3H), 1.092.15 (br, 2H), 3.05 ppm (s, 9H), 3.54 (br, 2H), 3.88 (s, 3H), 4.06 (br, 4H), 4.32 (br, 2H),
4.52 (br, 4H), 8.46 (s, 1H).

13

C NMR (125 MHz, TFE-d3, δ, ppm): 18.32, 19.81, 38.03,

46.54, 47.17, 55.97, 64.24, 64.99, 65.91, 66.68, 68.09, 128.59, 131.41, 138.82, 140.88,
162.72, 180.09. 31P NMR (202 MHz, TFE-d3, δ, ppm): - 2.36.

•

General procedure for the synthesis of a polyMPC macro-chain transfer agent
(macro-CTA) (P5)

In a 20-mL vial charged with a stir bar, MPC (3.90 g, 13.2 mmol), 4-cyano-4(phenylcarbonothioylthio)pentanoic acid (74.3 mg, 0.270 mmol), and ACVA (15.6 mg,
0.0560 mmol) were dissolved in MeOH (13.2 mL). The solution was degassed with
bubbling nitrogen at 0 °C for approximately 20 minutes and then was heated at 70 °C.
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Upon achieving monomer conversion ~ 80%, as estimated by 1H NMR spectroscopy, the
polymerization was terminated by exposure to air, and the solution was precipitated in
THF. The crude polymer was isolated by centrifugation (2000 rpm) and was dialyzed
against water. Lyophilization afforded P5 as a pink solid in yields >80%. Mn of the
polyMPC macro-CTA was estimated using 1H NMR spectroscopy by comparing signal
intensities at 3.66-3.82 ppm (CH2—N) (PC methylene protons) to that of the terminal
phenyl protons (7.40-7.96 ppm). 1H NMR (500 MHz, MeOD-d4, δ, ppm): 0.73-1.22 (br,
3H), 1.68-2.17 (br, 2H), 3.23-3.38 (s, 9H), 3.66-3.82 (br, 2H), 4.00-4.15 (br, 2H), 4.154.29 (br, 2H), 4.29-4.41 (br, 2H), 7.40-7.96.

31

P NMR (202 MHz, MeOD-d4, δ, ppm): -

0.45. Mn, NMR = 15,100-19,800 g/mol, Mn, TFE GPC = 20,900-21,900 g/mol, Ð = 1.05-1.13.

•

General procedure for the synthesis polyMPC-TMZ block copolymers (P6-P8)

In a 7-mL vial charged with a stir bar, polyMPC macro-CTA (P5), TMZ-methacrylate
(TMZ-MA), and ACVA were dissolved in TFE ([TMZ-MA]0 = 0.25 M), targeting
[ACVA]0:[P5]0: = 0.2:1 and [TMZ-MA]0:[P5]0 ranging from 17 to 37. The mixture was
purged with nitrogen gas at 0 °C for 15 minutes, then stirred at 70 °C to initiate
polymerization, judging monomer conversion by 1H NMR spectroscopy. At monomer
conversion >90%, the mixture was quenched in liquid nitrogen and exposed to air. The
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crude reaction mixture was precipitated three times from TFE into THF, and the polymer
was isolated by centrifugation. The isolated polymer was dissolved in aqueous 0.1 M HCl
(10 mL), added to a centrifugal dialysis filter with a nominal molecular weight cutoff of 10
kDa, and centrifuged (4000 x g, 30 minutes, room temperature). The filtrate was discarded,
and centrifugal dialysis was repeated twice. The concentrated polymer was dissolved in
aqueous 0.1 M HCl, and lyophilization afforded polymers P6-P8 as pink solids in yields
>50%. Incorporation of monomer TMZ-MA into the copolymer structure was estimated
by 1H NMR spectroscopy by comparing relative signal intensities at 8.72 ppm (C—H in
TMZ) and 2.78-3.22 ppm (N—(CH3)3 in MPC). 1H NMR (500 MHz, TFE-d3, δ, ppm):
0.00-1.07 (br, 6H), 1.25-2.13 (br, 4H), 2.78-3.22 (s, 9H), 3.53 (br, 2H), 3.88 (s, 3H), 3.934.26 (br, 4H), 4.34 (br, 2H), 4.43-4.75 (br, 4H), 8.72 (s, 1H). 13C NMR (125 MHz, TFEd3, δ, ppm): 18.47, 20.23, 38.51, 46.48, 46.95, 55.89, 62.81, 64.91, 65.94, 67.36, 67.88,
126.34, 131.34, 138.27, 140.01, 161.35, 179.79, 180.62. 31P NMR (202 MHz, TFE-d3, δ,
ppm): -2.79.

•

Synthesis of TMZ-methacrylamide (TMZ-Ma)

TMZ-Ma was synthesized following a modified literature procedure.5 In a 250-mL
round-bottom flask charged with a stir bar, cystamine hydrochloride (5.10 g, 22.6 mmol)
and triethylamine (9.5 mL, 68.2 mmol) were combined in methanol (70 mL). To this
mixture was slowly added a solution of di-tert-butyl dicarbonate (2.44 g, 11.2 mmol) in
methanol (45 mL) via addition funnel at 0 °C. The reaction mixture was stirred at room
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temperature for 16 h, after which the solvent was removed under reduced pressure. The
white residue was resuspended in 40 mL of aqueous 1 M NaH2PO4, and the solution was
washed with diethyl ether (3 × 40 mL). The pH of the aqueous phase was adjusted to
approximately pH 9 using aqueous 1 M NaOH, and the product was extracted into ethyl
acetate (3 × 40 mL). The organic fractions were combined, dried with anhydrous Na2SO4,
and concentrated under reduced pressure to give intermediate I1 as a viscous yellow oil
(1.97 g, 55% yield). 1H NMR (500 MHz, CDCl3, δ, ppm): 1.34 (br, 2H), 1.43 (s, 9H), 2.76
(m, 4H), 3.00 (t, 2H), 3.44 (q, 2H), 4.96 (br, 1H). 13C NMR (125 MHz, CDCl3, δ, ppm):
28.40, 38.39, 40.61, 45.52, 79.52, 155.75. Intermediate I2 was synthesized following a
modified literature procedure.5 To a dry 500-mL round-bottom flask charged with a stir
bar and flushed with nitrogen were added I1 (1.97 g, 7.79 mmol) and anhydrous DCM (100
mL). The mixture was cooled to 0 °C, and triethylamine (2.2 mL, 15.8 mmol) was added.
To this was slowly added a solution of methacryloyl chloride (1 mL, 10.1 mmol) in
anhydrous DCM (30 mL) via addition funnel, and the reaction was warmed to room
temperature. After 16 h, the reaction mixture was washed with saturated brine (3 × 45 mL),
dried over anhydrous Na2SO4, and concentrated under reduced pressure to give an offwhite solid. The crude product was purified by column chromatography on silica gel,
eluting with ethyl acetate:hexanes (1:1), to give I2 as a white solid (1.34 g, 54% yield). 1H
NMR (500 MHz, CDCl3, δ, ppm): 1.44 (s, 9H), 1.98 (s, 3H), 2.80 (t, 2H), 2.88 (t, 2H), 3.45
(q, 2H), 3.64 (q, 2H), 4.96 (br, 1H), 5.35 (s, 1H), 6.45 (br, 1H).

13

C NMR (125 MHz,

CDCl3, δ, ppm): 18.66, 28.39, 38.01, 38.23, 38.52, 39.39, 119.89, 139.81, 155.86, 168.58.
In a 20-mL vial charged with a stir bar, I2 (1.34 g, 4.18 mmol) was dissolved in DCM (6
mL). To this solution was added trifluoroacetic acid (5.65 mL), and the reaction mixture
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was stirred at room temperature. After 16 h, the solvent was removed under reduced
pressure to give the crude product as a viscous oil, which was then washed with diethyl
ether, yielding intermediate I3 as a white solid (1.0588 g, 76% yield). 1H NMR (500 MHz,
CDCl3, δ, ppm): 1.85 (s, 3H), 2.84 (t, 2H), 2.92 (t, 2H), 3.10 (t, 2H), 3.41 (q, 2H), 5.35 (s,
1H), 5.66 (s, 1H), 7.88 (s, 3H), 8.13 (t, 1H). 13C NMR (125 MHz, CDCl3, δ, ppm): 19.05,
34.65, 37.18, 38.29, 38.85, 119.79, 140.21, 168.04. In a 20-mL scintillation vial charged
with a stir bar, TMZ-carboxylic acid (352 mg, 1.81 mmol) was suspended in DCM (4 mL).
To this suspension was added I3 (449 mg, 1.34 mmol), catalytic DMAP (16.6 mg, 0.134
mmol), and EDC (393 mg, 1.5 eq., 2.05 mmol), giving a red homogenous reaction mixture.
This solution was stirred at room temperature for 16 h, after which the reaction had turned
opaque and orange. Sufficient DCM was added to the suspension to completely dissolve
the precipitate, and the organic phased was washed with aqueous 0.1 M HCl (3 × 40 mL).
The organic layer was then dried over Na2SO4 and concentrated under reduced pressure,
giving TMZ-methacrylamide (TMZ-Ma) as a white solid (454 mg, 85% yield). 1H NMR
(500 MHz, DMSO, δ, ppm): 1.84 (s, 3H), 2.85 (t, 2H), 2.94 (t, 2H), 3.41 (q, 2H), 3.61 (q,
2H), 3.86 (s, 3H), 5.33 (s, 1H), 5.66 (s, 1H), 8.09 (t, 1H), 8.65 (t, 1H), 8.85 (s, 1H).

13

C

NMR (125 MHz, DMSO, δ, ppm): 19.05, 36.63, 37.49, 38.49, 38.93, 119.72. 128.96,
130.58, 135.05, 139.67, 140.23, 160.22, 167.96. HRMS-FAB (m/z): [M+H]+ calculated for
C14H22N7O3S2: 398.4899; found: 398.1069.

•

Synthesis of TMZ-thiol
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In a 50-mL round-bottom flask charged with a stir bar, cysteamine (3.34 g, 43.3 mmol)
was dissolved in TFA (30 mL). To this was added trityl chloride (12.1 g, 43.3 mmol), and
the reaction mixture was stirred overnight at room temperature. After 16 h, the solution
was concentrated by rotary evaporation. The crude product was suspended in ethyl acetate
(50 mL) and washed with aqueous 3 M NaOH (3 × 15 mL), water (15 mL), saturated
NaHCO3 (2 × 15 mL), and brine (3 × 15 mL). The organic layer was dried over Na2SO4,
and a precipitate was observed. To the suspension was added chloroform, and the
suspension was heated to dissolve the precipitant. The solution was concentrated by rotary
evaporation, and the crude product was recrystallized from hexanes:DCM (1:1) to give
trityl-protected cysteamine as a white solid (2.64, 14% yield). Then, in a 20-mL vial
charged with a stir bar, TMZ-carboxylic acid (893 mg, 4.66 mmol), trityl-protected
cysteamine (1.66 g, 3.80 mmol), and DMAP (49.4 mg, 0.400 mmol) were suspended in 10
mL of DCM. To this suspension was added TEA (585 μL, 4.20 mmol), and the vial was
cooled to 0 °C. EDC (1.16 g, 6.10 mmol) was added to the suspension; the mixture became
homogeneous and red. After stirring at room temperature for 20 h, the solution was diluted
with DCM (20 mL) and washed with aqueous 0.1 M HCl (3 × 50 mL). The organic layer
was dried over Na2SO4 and concentrated by rotary evaporation. To a 20-mL vial charged
with a stir bar, the crude product was combined with TFA (2 mL) and dissolved in DCM
(2 mL). To this was added triisopropylsilane (1 mL), and the reaction was allowed to stir
at room temperature. After 1 h, the solution was concentrated by rotary evaporation and
purified by column chromatography on silica gel, eluting with ethyl acetate, to give TMZthiol 7 as a white solid (487.5 mg, 42% yield). 1H NMR (400 MHz, DMSO, δ, ppm): 2.43
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(t, 1H), 2.67 (q, 2H), 3.46 (q, 2H), 3.87 (s, 3H), 8.64 (t, 1H), 8.85 (s, 1H). 13C NMR (100
MHz, DMSO, δ, ppm): 23.33, 36.15, 41.94, 128.47, 130.18, 134.51, 139.19, 159.65.

•

General procedure for the synthesis of polyMPC-butyl methacrylate (BMA)
random copolymer

A polyMPC-b-poly(butyl methacrylate) (polyMPC-BMA) copolymer was prepared by
Matthew Skinner by chain extension using polyMPC macro-CTA P5. In a 7 mL vial
charged with a stir bar, P5 (439.3 mg, 0.022 mmol), BMA (140 µL, 0.88 mmol), and
ACVA (1.23 mg, 0.0044 mmol) were dissolved in MeOH (1.76 mL). The solution was
purged with nitrogen gas at room temperature for approximately 15 minutes and was heated
at 70 °C to initiate polymerization. After 18 hours, the solution was opened to ambient
atmosphere and precipitated in THF (30 mL). The crude polymer was isolated by
centrifugation (3000 rpm) and dialyzed against water. Lyophilization afforded polyMPCBMA as a pink solid in 81% yield. Incorporation of BMA into the copolymer structure was
estimated by 1H NMR spectroscopy by comparing relative signal intensities at 1.37-1.74
ppm (CH2—CH2 in BMA) and 3.66-3.84 ppm (N—CH2 in MPC). 1H-NMR (500 MHz,
MeOD-d4, δ, 154 ppm): 0.73-1.21 (m, 7H), 1.37-1.74 (m, 4H), 1.74-2.20 (b, 2H), 3.32 (s,
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9H), 3.76 (br, 2H), 3.98 (br, 2H), 4.09 (br, 2H), 4.24 (br, 2H), 4.34 (br, 2H), 7.38-7.94. 31P
NMR (202 MHz, MeOD-d4, δ, ppm): -0.47. Mn, TFE GPC = 29,400 g/mol, PDI = 1.16.

•

General procedure for the synthesis of fluorescent polyMPC-TMZ random
copolymers (P9-P10)

P9-P10 were synthesized by Matthew Skinner. In a 7 mL vial charged with a stir bar,
MPC and TMZ-MA were dissolved in TFE at a total monomer concentration of 0.75-1 M.
Fluorescein O-methacrylate, 4-cyano-4- (phenylcarbonothioylthio)pentanoic acid (CTA),
and ACVA were added to the solution, targeting [monomer]0:[fluorescein Omethacrylate]0:[CTA]0:[ACVA]0 of 102:1:1:0.2. The solution was degassed at 0 °C with
nitrogen gas for approximately 15 minutes, and was heated at 70 °C, protected from light,
to initiate polymerization. Upon reaching monomer conversion >75%, the polymerization
was quenched in liquid nitrogen and exposed to air. The crude polymer was purified by
precipitation from TFE into THF (6 times), isolated by centrifugation (2000 rpm), and dried
under vacuum. The polymer pellet was purified by centrifugal dialysis against aqueous 0.1
M HCl as described previously for polyMPC-TMZ copolymers P27-P30. Fluoresceincontaining polymers P9 and P10 were isolated by lyophilization and isolated as yellow and
red solids, respectively, in yields of 55-59%. Incorporation of TMZ-MA into the
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copolymer structure was estimated by 1H NMR spectroscopy by comparing relative signal
intensities at 8.58 ppm (TMZ) and 2.87-3.35 ppm (MPC). Fluorescein incorporation was
estimated by fluorescence spectroscopy: P9 = 0.067 weight %; P10 = 0.068 weight %. P9:
Mn, TFE GPC = 37,300 g/mol, Đ = 1.19. P10: Mn, TFE GPC = 37,000 g/mol, Đ = 1.20.

•

General procedure for the synthesis of fluorescent polyMPC (P13)

P13 was synthesized by Matthew Skinner. In a 7-mL vial charged with a stir bar, MPC
(993.2 mg, 3.36 mmol), fluorescein O-methacrylate (14.0 mg, 0.035 mmol), 4-cyano-4(phenylcarbonothioylthio)pentanoic acid (18.7 mg, 0.067 mmol), and ACVA (3.6 mg,
0.013 mmol) were dissolved in TFE (4.46 mL). The solution was purged at room
temperature with nitrogen gas, and was heated at 70 °C, protected from light, to initiate
polymerization. A monomer conversion of 67% was achieved in 5.5 hours, and the
polymerization solution was quenched in liquid nitrogen and was exposed to air. The crude
polymer was repeatedly precipitated into THF to remove unreacted monomer and was
isolated by centrifugation. The polymer was dialyzed against water, protected from the
light, and isolated by lyophilization. Fluorescent P13 was isolated as a light yellow solid
in 38% yield. Fluorescein incorporation was estimated by fluorescence spectroscopy: P13
= 0.32 weight %. 1H NMR (500 MHz, MeOD-d4, δ, ppm): 0.65-1.62 (br, 3H), 1.66-2.20
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(br, 2H), 3.79-3.39 (s, 9H), 3.64-3.84 (br, 2H), 3.99-4.16 (br, 2H), 4.16-4.29 (br, 2H), 4.294.42 (br, 2H), 7.41-7.96. 31P NMR (202 MHz, MeOD-d4, δ, ppm): -0.47 ppm. Mn, NMR =
24,500 g/mol, Mn, TFE GPC = 21,000, Đ = 1.13.

•

General procedure for the synthesis of fluorescent polyMPC-TMZ block
copolymers (P11-P12)

P11-P12 were synthesized by Matthew Skinner. In a 7 mL vial charged with a stir bar,
fluorescent polyMPC macro-CTA P13, TMZ-MA, and ACVA were dissolved in TFE
([TMZ-MA] = 0.25 M), targeting [ACVA]0:[P13]0: = 0.2:1 and [TMZ-MA]0:[P13]0 of 18
(P11) or 49 (P12). The mixture was purged with nitrogen gas at 0 °C for 15 minutes, then
stirred at 70 °C, protected from the light, to initiate polymerization. At monomer
conversion >85%, the mixture was quenched in liquid nitrogen and was exposed to air. The
crude polymers were then purified in similar fashion as block copolymers P6-P8.
Lyophilization afforded polymers P11 and P12 in yields of 45-66%. Incorporation of
TMZ-MA into the copolymer structure was estimated by 1H-NMR spectroscopy.
Fluorescein incorporation was estimated by fluorescence spectroscopy: P11 = 0.032
weight %; P12 = 0.021 weight %. 1H NMR (500 MHz, TFE-d3, δ, ppm): -0.33-1.58 (br,
6H), 1.61-2.30 (br, 4H), 2.88-3.49 ppm (s, 9H), 3.62 (br, 2H), 3.95 (s, 3H), 4.05- 4.34 (br,
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4H), 4.42 (br, 2H), 4.53-4.82 (br, 4H), 8.64 (s, 1H). 31P NMR (202 MHz, TFE-d3, δ, ppm):
-2.61.

•

General procedure for the synthesis of disulfide-containing polyMPC-TMZ
random copolymers (P14-P15)

In a 7-mL vial charged with a stir bar, MPC and TMZ-methacrylamide (TMZ-Ma)
were dissolved in TFE at a total monomer concentration of 0.75 M. ACVA and 4-cyano4-(phenylcarbonothioylthio)pentanoic acid were added as the radical initiator (I) and chaintransfer agent (CTA), respectively, targeting [CTA]0:[I]0 of 5:1 and [MPC]0:[TMZ-Ma]0
ranging from 85:15 to 55:55. The solution was degassed with bubbling nitrogen at room
temperature for approximately 15 minutes and then was heated to 70 °C to initiate
polymerization. Upon achieving monomer conversion >80%, as estimated by 1H NMR
spectroscopy, the polymerization was quenched into a liquid nitrogen bath and exposed to
air. The mixture was precipitated three times from TFE into THF, and the polymer was
isolated by centrifugation. The isolated polymer was dissolved in aqueous 0.1 M HCl (10
mL), added to a centrifugal dialysis filter with a nominal molecular weight cutoff of 10
kDa, and centrifuged (4000 x g, 45 minutes, room temperature). The filtrate was discarded,
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and centrifugal dialysis was repeated twice. The concentrated polymer was dissolved in
aqueous 0.1 M HCl, and lyophilization afforded polymers P14-P15 as pink solids in yields
>60%. Incorporation of monomer TMZ-Ma into the copolymer structure was estimated
by 1H NMR spectroscopy by comparing the relative signal intensities at 8.50 ppm (C—H
in TMZ) and 3.16-3.49 ppm (N—(CH3)3 in MPC). 1H NMR (500 MHz, TFE-d3, δ, ppm):
0.05-1.28 (br, 6H), 1.29-2.33 (br, 4H), 2.53-2.93 (br, 4H), 3.08 (s, 9H), 3.25-3.48 (br, 2H),
3.48-3.65 (br, 3H), 3.77-3.95 (br, 4H), 3.96-4.30 (br, 4H), 4.33-4.50 (br, 2H), 8.42 (s, 1H).
C NMR (125 MHz, TFE-d3, δ, ppm): 17.18, 18.53, 35.99, 38.22, 39.28, 45.25, 53.92,
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54.75, 63.83, 65.50, 65.92, 134.30, 138.40, 160.38, 177.86, 178.83. 31P NMR (202 MHz,
TFE-d3, δ, ppm): -2.68.

•

General procedure for the synthesis of polyMPC-PDS-TMZ random copolymers
(P16)

PolyMPC-PDS-TMZ random copolymers were prepared in conjunction with Matthew
Skinner. In a 7-mL vial charged with a stir bar, MPC, PDS-MA, and TMZ-MA were
dissolved in TFE at a total monomer concentration of 1.0 M. ACVA and 4-cyano-4(phenylcarbonothioylthio)pentanoic acid were added as the radical initiator (I) and chaintransfer agent (CTA), respectively, targeting [CTA]0:[I]0 of 5:1 and [MPC]0:[PDS-
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MA]0:[TMZ-Ma]0 of 53:28:28. The solution was degassed with bubbling nitrogen at room
temperature for approximately 15 minutes and then was heated to 70 °C to initiate
polymerization. Upon achieving monomer conversion >80%, the polymerization was
quenched by exposure to air. The mixture was precipitated three times from TFE into THF.
The isolated polymer was dissolved into aqueous 0.1 M HCl (10 mL), added to a
centrifugal dialysis filter with a nominal molecular weight cutoff of 10 kDa, and
centrifuged (4000 x g, 45 minutes, room temperature). The filtrate was discarded, and
centrifugal dialysis was repeated twice. The concentrated polymer was dissolved in
aqueous 0.1 M HCl, and lyophilization afforded P16 as a pink solid in yields >60%. 1H
NMR (500 MHz, TFE-d3, δ, ppm): 0.42-1.39 (br, 9H), 1.39-2.40 (br, 6H), 3.05-3.53 (s,
9H), 3.61-3.85 (s, 2H), 4.02-4.62 (m, 13H), 4.62-5.06 (br, 4H), 7.74-7.93 (s, 1H), 8.238.55 (m, 2H), 8.55-8.82 (br, 2H). Mn, NMR = 20,400-24,900 g/mol, Mn, TFE GPC = 30,900
g/mol, Ð = 1.13.

•

General procedure for the synthesis of a polyMPC-PDS macro-CTA (P17)

PolyMPC-PDS macro-CTA was prepared in conjunction with Matthew Skinner. In a
7-mL

vial

charged

with

a

stir

bar,

MPC,

PDS-MA,

4-cyano-4-

(phenylcarbonothioylthio)pentanoic acid, and ACVA were dissolved in TFE ([monomer]
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= 1.0 M), targeting [CTA]0:[I]0 of 5:1 and [MPC]0:[PDS-MA]0:[CTA]0 of 38:12:1. Upon
achieving monomer conversion ~ 80%, the polymerization was terminated by exposure to
air, and the solution was precipitated in THF. The crude polymer was isolated by
centrifugation (2000 rpm) and was dialyzed against water. Lyophilization afforded P17 as
a pink solid in yields >60%. 1H NMR (500 MHz, MeOD-d4, δ, ppm): 0.77-1.23 (br, 6H),
1.66-2.21 (br, 4H), 3.25-3.42 (s, 9H), 3.71-3.89 (s, 2H), 4.02-4.53 (m, 10H), 7.34-7.52 (s,
1H), 7.90-8.13 (s, 2H), 8.47-8.63 (s, 1H). Mn, NMR = 14,000-20,100 g/mol, Mn, TFE GPC =
22,000-25,500 g/mol, Ð = 1.08-1.13.

•

General procedure for the synthesis of polyMPC-PDS-TMZ block copolymers
(P18)

PolyMPC-PDS-TMZ block copolymers were prepared in conjunction with Matthew
Skinner. In a 7-mL vial charged with a stir bar, polyMPC-PDS macro-CTA P17, TMZMA, and ACVA were dissolved in TFE ([TMZ-MA]0 = 0.25 M), targeting
[ACVA]0:[P17]0: = 0.2:1 and [TMZ-MA]0:[P17]0 = 26:1. The mixture was purged with
nitrogen gas at 0 °C for 15 minutes, then stirred at 70 °C to initiate polymerization. At
monomer conversion >90%, the mixture was quenched in liquid nitrogen and exposed to
air. The crude reaction mixture was precipitated three times from TFE into THF, and the
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polymer was isolated by centrifugation. The isolated polymer was dissolved in aqueous 0.1
M HCl (10 mL), added to a centrifugal dialysis filter with a nominal molecular weight
cutoff of 10 kDa, and centrifuged (4000 x g, 30 minutes, room temperature). The filtrate
was discarded, and centrifugal dialysis was repeated twice. The concentrated polymer was
dissolved in aqueous 0.1 M HCl, and lyophilization afforded polymer P18 as pink solids
in yields >60%. 1H NMR (500 MHz, TFE-d3, δ, ppm): 0.36-1.52 (m, 9H), 1.52-2.54 (br,
6H), 3.07-3.56 (s, 9H), 3.07-3.89 (s, 2H), 4.06-4.73 (m, 13H), 4.73-4.97 (br, 4H), 7.827.98 (s, 1H), 8.26-8.52 (s, 1H), 8.52-8.63 (s, 1H), 8.68-8.82 (s, 1H), 8.82-9.07 (s 1H). Mn,
NMR

•

= 27,100 g/mol, Mn, TFE GPC = 25,800 g/mol, Ð = 1.08.

General procedure for the disulfide exchange to prepare polyMPC-DSF (P19)

In a 7-mL vial charged with a stir bar, copolymer P17 was dissolved at a concentration
of 50 mg/mL in either aqueous 0.1 M HCl or TFE (with catalytic acetic acid), and
diethyldithiocarbamic acid sodium salt trihydrate (SDT) was added (10 molar eq. to PDS).
After 16 h, the crude polymer was precipitated into THF and collected by centrifugation.
The isolated polymer was dissolved in aqueous 0.1 M HCl (10 mL), added to a centrifugal
dialysis filter with a nominal molecular weight cutoff of 10 kDa, and centrifuged (4000 x
g, 30 minutes, room temperature). The filtrate was discarded, and centrifugal dialysis was
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repeated twice. The concentrated polymer was dissolved in aqueous 0.1 M HCl, and
lyophilization afforded polymer P19 in 90% yield. 1H NMR (500 MHz, MeOD-d4, δ, ppm):
0.79-1.48 (br), 1.48-2.42 (br), 3.13-3.49 (s), 3.67-3.88 (br), 4.02-4.4 (m), 4.52-4.74 (s).

•

General procedure for the preparation of polyMPC-DSF-TMZ random
copolymers (P20-P21)

DSF-containing copolymers P20-P21 were prepared according to the same procedure
used for polymer P19.

•

General procedure for the preparation of polyMPC-TMZ-TMZ random and
block copolymers (P22-P23)
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The same procedure was utilized for both random and block copolymer architectures.
In a 7-mL charged with a stir bar, copolymer P16 or P18 was dissolved at a concentration
of 50 mg/mL in TFE (with catalytic acetic acid), and TMZ-thiol was added (5 molar eq. to
PDS). After 16 h, the crude polymer was precipitated into THF and collected by
centrifugation. The isolated polymer was dissolved in minimal aqueous 0.1 M HCl, added
to a centrifugal dialysis filter with a nominal molecular weight cutoff of 10 kDa, and
centrifuged (4000 x g, 30 minutes, room temperature). The filtrate was discarded, and
centrifugal dialysis was repeated twice. The concentrated polymer was dissolved in
aqueous 0.1 M HCl, and lyophilization afforded polymers P22-P23 in >80% yields. 1H
NMR (500 MHz, TFE-d3, δ, ppm): 0.53-1.50 (br), 1.50-2.53 (br), 2.90-3.18 (s), 3.18-3.52
(s), 3.70-3.87 (s), 4.01-4.50 (m), 4.50-4.72 (s), 4.72-5.03 (br), 8.62-8.95 (m).

•

General procedure for the synthesis of polyGEM (P24)

Several polymerization conditions were attempted and are briefly summarized here.
Detailed solvent and concentration combinations can be found in Chapter 3. The free
radical polymerization of P24 was conducted at 70 °C in DMF at a monomer concentration
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of 0.5 M, using ACVA as the initiator ([ACVA]0:[GEM-MA]0 = 1:50). Postpolymerization purification was not attempted. For RAFT polymerizations, a general
procedure is as follows: in a 7-mL vial charged with a stir bar GEM-MA was dissolved in
DMF ([GEM] = 0.5 M). ACVA and the appropriate CTA (CTA 1 or CTA 2) were added,
targeting [CTA]0:[ACVA]0 = 5:1 and [CTA]0:[GEM-MA]0 = 1:50. Post-polymerization
was not attempted, but 1H NMR spectroscopy was used to determine monomer conversion.

•

General procedure for the synthesis of polyMPC-GEM random copolymers (P25P27)

Several polymerization conditions were attempted and are briefly summarized here.
Detailed solvent and concentration combinations can be found in Chapter 3. Free radical
polymerizations were performed as described for P24, but post-polymerization purification
was not attempted. For RAFT polymerizations, a general procedure is as follows: in a 7mL vial charged with a stir bar, MPC and gemcitabine-methacrylate (GEM-MA) were
dissolved in methanol at a total monomer concentration of 0.5 M. ACVA and the
appropriate CTA (CTA 1 or CTA 2) were added, targeting [CTA]0:[ACVA]0 = 5:1 and
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[MPC]0:[GEM-MA]0 ranging from 75:25 to 50:50. The solution was degassed with
bubbling nitrogen at room temperature for approximately 15 minutes and then was heated
to 70 °C to initiate polymerization. After 16-18 h, the reaction was quenched into a liquid
nitrogen bath and exposed to air. The mixture was precipitated into THF, and the polymer
was isolated by centrifugation. The isolated polymer was dissolved in water and dialyzed
(using tubing with a nominal molecular weight cutoff of 3.5 kDa). Lyophilization afforded
polymers P25-P27 in yields >50%. Incorporation of monomer GEM-MA was estimated
by UV-vis spectroscopy. Solubility issues prevented accurate 1H NMR spectroscopy.

•

General procedure for the synthesis of a polyMPC macro-CTA with CTA 2 (P28)

In a 7-mL vial charged with a stir bar, MPC, 2-cyano-2-propyl dodecyl trithiocarbonate
(CTA 2), and ACVA were dissolved in MeOH. The solution was degassed with bubbling
nitrogen for 15 minutes and then was heated at 70 °C to initiate polymerization. Upon
achieving monomer conversion of ~80%, the polymerization was terminated by exposure
to air, and the solution was precipitated in THF. The crude polymer was isolated by
centrifugation (2000 rpm) and was dialyzed against water. Lyophilization afforded P28 as
a pink solid in 80% yield. 1H NMR spectroscopy matches P5.
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•

General procedure for the synthesis of polyMPC-GEM block copolymers (P29P32)

In a 7-mL vial charged with a star bar, polyMPC macro-CTA P28, GEM-MA, and
ACVA were dissolved in MeOH ([GEM-MA]0 = 0.25 M), targeting [ACVA]0:[P28]0 =
0.2:1 and [GEM-MA]0:[P28]0 ranging from 17 to 37. The mixture was degassed with
bubbling nitrogen for 15 minutes, then stirred at 70 °C to initiate polymerization. After 4
h, the reaction was quenched in a liquid nitrogen bath and exposed to air, and the solution
was precipitated in THF. The crude polymer was isolated by centrifugation (2000 rpm) and
was dialyzed against water. Lyophilization afforded P29-P32 as a pink solids in 60% yield.
Incorporation of monomer GEM-MA was estimated by UV-vis spectroscopy. Solubility
issues prevented accurate 1H NMR spectroscopy.

•

General procedure for incorporating TMZ monomers into PC-PEG hydrogels
(C1-C4)
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MPC (15 weight/volume %), PEGDMA Mn 1000 (5 or 10 weight/volume %), and a
TMZ-containing monomer (TMZ-MA or TMZ-Ma; 5 weight/volume %) were combined
in a 7-mL vial. Irgacure 2959 (1 weight/volume %) was added as the radical photoinitiator.
The solutions were degassed with bubbling nitrogen, and gel formation was induced by
irradiation for 30 minutes at λ = 365 nm in a UV box (~3.5 mW/cm2; model CL-1000L,
Upland, CA).

•

General procedure for the preparation of H1-H2 and H15
Solutions of 40 mg/mL random polyMPC-TMZ copolymer (having either 25 or 50

weight % TMZ) were prepared by dissolution of polymer into 0.1 M HCl, pH 4.5 citrate
buffer, or pH 7.4 phosphate-buffered saline. PC-PEG hydrogels were prepared by mixing
PEGDMA (average Mn 1000) (25 weight %), MPC (75 weight %), and VA-044 (1.2
weight/volume %) with 1 mL of the random copolymer solution. Hydrogel precursor
solutions were degassed for 30 seconds with nitrogen, then placed into 24-well cell plates.
Gel formation was induced by irradiation for 6 minutes at λ = 365 nm in a UV box.
Following hydrogel formation, the gels were frozen and lyophilized to yield solid pink
pellets which could be easily removed from the cell plates. H1 prepared in a 96-well plate
is referred to as H15.

•

General procedure for the preparation of H3-H6
Nanoscale aggregates of polyMPC-TMZ were prepared by dissolution of polymer into

0.1 M HCl, pH 4.5 citrate buffer, or pH 7.4 phosphate-buffered saline at 5 mg/mL (above
the CAC6). Polymer solutions were used to suspend native TMZ at a free drug
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concentration of 5 mg/mL. PC-PEG hydrogels were prepared by mixing PEGDMA
(average Mn 1000) at varying concentrations (12, 25, 35, 50 weight %), MPC (88, 75, 65,
50 weight %), and VA-044 (1.2 weight/volume %) with 1 mL of polymer solutions with
suspended TMZ. Solutions were degassed for 30 seconds with nitrogen, then placed into
24- or 96-well cel plates. Gel formation was induced by irradiation for 6 minutes at λ = 365
nm in a UV box. Following hydrogel formation, the gels were frozen and lyophilized to
yield solid white pellets which could be easily removed from the cell plates.

•

General procedure for the preparation of hydrogels using Irgacure 2959 (H#I)
PC-PEG hydrogels were prepared by mixing PEGDMA (average Mn 1000) at varying

concentrations (25 weight %), MPC (75 weight %), and Irgacure 2959 (1.2 weight/volume
%). Solutions were degassed for 30 seconds with nitrogen, then placed into 96-well cell
plates. Gel formation was induced by irradiation for 12 minutes at λ = 365 nm in a UV box.
Pellets containing TMZ were prepared using solutions described for H3-H6 above.

•

General procedure for the preparation of H7-H10
PC-PEG hydrogels prepared with lower concentrations of VA-044 were prepared as

described for H1-H6 with 25 weight % PEGDMA and between 0.01-1.2 weight/volume %
VA-044.

•

General procedure for the preparation and evaluation of H11-H14
TMZ uptake into PC-PEG hydrogels was conducted using a 40 mg/mL solution of

random polyMPC-TMZ copolymer (25 weight % TMZ) in pH 7.4 PBS. Pellets prepared
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without TMZ initially (H7; 0.1 weight/volume % VA-044) were placed in a 48-well cell
plate, and 330 μL of polymer solution was added to each gel. The polymer solution was
decanted at predetermined intervals (10, 20, 30, or 60 minutes), and the swollen gels were
placed into 20 mL of pH 4.5 citrate buffer and incubated at 37 °C. TMZ release was
monitored as described below.

•

General procedure for the preparation of H16-H19
Nanoscale aggregates of polyMPC-TMZ were prepared by dissolution of polymer into

pH 7.4 PBS saline at 5 mg/mL (above the CAC6). Polymer solutions were used to suspend
native TMZ at a free drug concentration of 5 mg/mL. TMZ uptake into PC-PEG hydrogels
was conducted using this polyMPC-TMZ/TMZ solution. Pellets prepared without TMZ
initially (H7; 0.1 weight/volume % VA-044) were placed in a 48-well cell plate, and 330
μL of polyMPC-TMZ/TMZ solution was added to each gel. The polymer solution was
decanted at predetermined intervals (10, 20, 30, or 60 minutes), and the swollen gels were
placed into 20 mL of pH 4.5 citrate buffer and incubated at 37 °C. TMZ release was
monitored as described below.

•

General procedure for UV-vis degradation studies
The degradation of TMZ and polyMPC-TMZ conjugates under physiological

conditions was assessed using UV-vis spectroscopy. Pure TMZ and polyMPC-TMZ
copolymers were prepared as 1 mg/mL solutions in phosphate-buffered saline (PBS) at pH
7.4. For polyMPC-TMZ conjugates containing disulfide linkers (P14-P1 and P22-P23),
copolymers were prepared as 1 mg/mL solutions in phosphate-buffered saline (PBS)
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enriched with GSH (2 μM or 1 mM) or DTT (3 mM) at pH 7.4. The solutions were diluted
to an approximate TMZ-equivalent concentration of 0.013 mg/mL, then transferred to
quartz cuvettes containing a magnetic stir bar. Solutions were incubated at 37 °C while
stirring at 500 rpm in the UV-vis spectrometer, and absorbance spectra (λ = 200-450 nm)
were measured at pre-determined intervals. The decrease in absorbance intensity at λ =
328-330 nm, corresponding to the urea of intact TMZ, was measured, and exponential
decay curves were generated from plotting the normalized absorbance (A/A0) as a function
of time. Fitting these curves gave the decay constant, which was used to determine the t1/2
of free TMZ and polyMPC-TMZ copolymers.

•

General procedure for DLS of polyMPC-TMZ copolymers (P1-P4 and P6-P8)
1 mg/mL suspensions of polyMPC-TMZ copolymers P1-P4 and P6-P8 were prepared

in pH 7.4 PBS. The suspensions were passed through 0.45 µm cellulose acetate filters into
disposable cuvettes and analyzed by DLS at 37 °C. Three measurements were made for
each suspension, with measurements consisting of 10 runs each.

•

Cell culture of polymer injectables
U87MG and T98G glioblastoma cells were cultured in DMEM medium supplemented

with 10% fetal bovine serum (FBS) and antibiotic-antimycotic solution (1×). All cells were
grown in 5% CO2 incubators at 37 °C. For all cytotoxicity assays, cell viability was
measured post-treatment using CellTiter-Glo® luminescent viability assays following
manufacturer instructions (Promega) on a FLUOstar OPTIMA plate reader (BMG
LABTECH). The percentage of TMZ-mediated toxicity was calculated relative to
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untreated cells and plotted to give dose-response curves. IC50 values for each treatment
were calculated using GraphPad Prism 7 software. In vitro cytotoxicity assays were
performed by seeding U87MG and T98G cells in 96-well plates (~1-2 × 103 cells per plate).
The cells were then incubated for 6 days with a range of TMZ-equivalent concentrations
(1-20,000 μM) of free TMZ, polyMPC-TMZ conjugates P1-P4 and P6-P8, and polyMPC
as a control (20,000 μM). To evaluate cytotoxicity of disulfide-containing conjugates,
U87MG cells were seeded in 96-well plates (~2 × 103 cells per plate). The cells were then
incubated for 6 days with a range of TMZ-equivalent concentrations (1-10,000 μM) of free
TMZ, TMZ-thiol 7, disulfide-containing polyMPC-TMZ copolymers P14-P15, and
polyMPC as a control (20,000 μM) in the presence of 0 or 1 mM GSH.

•

Evaluation of cellular uptake of polymer injectables
U87MG cells were placed on 35 mm dishes with 10 mM glass microwells (Mattek)

overnight. The following day, cells were treated P9-P13 at polymer concentrations of 200
μM for 2 h. Following incubation, cells were washed 3 times with PBS and incubated with
a 50 mM solution of Lysotracker Red for 10 min. Cells were then washed 3 times with
PBS and fixed with 4% paraformaldehyde in PBS for 5 min. Cells were then washed 3
times with PBS, incubated with a DAPI solution, and examined by confocal microscopy.
In addition to confocal microscopy, flow cytometry was performed to quantify cellular
uptake of fluorescently labeled polyMPC and polyMPC-TMZ conjugates. U87MG cells
were grown in T-25 tissue culture flasks and treated with P9-P13 at polymer concentrations
of 200 μM. After 2 h, the cells were trypsinized and washed with PBS. Fluorescence was
detected using a BD DUAL LSRFortessa flow cytometer, and the data analyzed using
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FlowJo software. The mean fluorescence intensity was calculated using the relative
incorporation of fluorophore in each conjugate, as estimated by a fluorescein calibration
curve.

•

TMZ release from staggered release copolymers P22-P23
Release of TMZ from polyMPC-dsTMZ-TMZ copolymers was monitored by dialysis.

Lyophilized polymers were dissolved in either pH 4.5 citrate buffer or pH 7.4 PBS at
concentrations ranging from 5-10 mg/mL. The solution was transferred to a dialysis
cassette (molecular weight cutoff 3,500 g/mol) by syringe. The cassette was suspended in
a sealed container with 200 or 225 mL of pH 4.5 citrate buffer, pH 7.4 PBS, or buffer
enriched with 3 mM DTT. Containers were incubated at 37 °C, and at select time points 1
mL aliquots were removed from the external media and replaced with fresh buffer. The
UV-vis absorbance spectra (λ = 200-450 nm) were measured and the peak at λ = 328-330
nm, corresponding to the urea of intact TMZ, was monitored until a plateau was reached.

•

Hydrogel swelling characterization
All hydrogels were incubated for 72 h in 37 °C pH 7.4 PBS to determine their swollen

mass and volume. Post-swelling hydrogel dimensions were estimated using ImageJ. The
mass and volume swelling ratios were calculated using the following:
𝑅𝑠 =

𝑉𝑠 − 𝑉𝑑
× 100
𝑉𝑑

where Vs and Vd are the volumes of swollen and dry hydrogels, respectively (or, in the case
of the mass swelling ratio, Ws and Wd are used). The experiments were performed in
triplicate. Error was represented as the standard deviation. The average mesh size (ξ) was
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determined as a function of the PEDGMA content according to the Flory theory, as
modified by Canal and Peppas:7
−1/3

𝜉 = 𝜐2,𝑠 (𝑟̅ 2 )1/2
where 𝜐2,3 is the swollen volume fraction of the polymer and (𝑟̅ 2)1/2 is the average end-toend distance of the PEGDMA crosslinker and is further represented as:
1/2

𝑁1/2 𝑏𝐶𝑛

where N is the number of PEG segments, b is the segment length of PEG, and Cn is the
Flory characteristic ratio of PEG.

•

Hydrogel mechanical characterization
PC-PEG hydrogels (without TMZ) for rheological testing were formed in silicone

molds at PEGDMA concentrations of 12, 25, 35, and 50 weight % and swelled in pH 7.4
PBS for 72 h. After swelling, oscillatory frequency sweeps were performed on the
hydrogels with an angular frequency of 0.1 to 10 radians/s with 5% strain. Gap heights
were set to 800 μm. PC-PEG hydrogels (without TMZ) for DMA testing were formed in
24-well untreated cell plates at PEGDMA concentrations of 12, 25, 35, and 50 weight %
and swelled in pH 7.4 PBS for 72 h. Compression tests were performed on samples with a
thickness of 5 ± 0.5 mm and diameter dimensions of 17 ± 0.5 mm, at a constant
displacement rate of 2 μm/s. The Young’s modulus (E) was calculated from the slope of
the stress-strain curve in the range of 0-5% strain.

•

TMZ release from hydrogels
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Release of TMZ from the hydrogels at pH 4.5 and pH 7.4 was monitored by UV-vis
spectroscopy. Briefly, hydrogels were placed in sealed containers with 225 mL pH 4.5
citrate buffer or pH 7.4 phosphate-buffered saline (PBS). Containers were incubated at 37
°C, and 1 mL aliquots were removed at predetermined time points and replaced with fresh
buffer. Aliquots were diluted with an additional 2 mL of buffer for UV-vis measurements.
For TMZ release from H11-H14 and H16-H19 (conducted in 20 mL buffer reservoirs),
100 μL were removed (replaced with fresh buffer) and diluted with 2.7 or 2.4 mL fresh
buffer, respectively, for UV-vis measurements. The absorbance intensity at λ = 329 nm,
corresponding to the urea of intact TMZ, was measured and the percent of maximum TMZ
was determined by comparison to a calibration curve. Similarly, the absorbance intensity
at λ = 267 nm, corresponding to the amide of the AIC by-product, was measured and the
percent of maximum AIC was determined by comparison to a calibration curve.

•

Cell culture of hydrogels
U87MG glioblastoma and HEK293A cells were cultured in in DMEM medium

supplemented with 10% fetal bovine serum (FBS) and antibiotic-antimycotic solution (1×).
All cells were grown in 5% CO2 incubators at 37 °C. Cell viability was measured posttreatment using a CellTiter-Glo® luminescent viability assays following manufacturer
instructions (Promega) on a FLUOstar OPTIMA plate reader (BMG LABTECH). In vitro
cytotoxicity assays were performed by seeding U87MG and H293A cells in 96-well plates
(density). The cells were then incubated for 48 or 72 hours with lyophilized pellets having
a range of PEGDMA concentrations, VA-044 weight %, and TMZ incorporation. Cells
alone served as a negative control in all cases. For evaluations on the effect of washing on
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cell viability, hydrogels were washed in 48-well cell plates under the following conditions:
(1) water 2 x 24 h, followed by serum-free medium (SFM) 2 x 24 h; (2) SFM 4 x 24 h; (3)
water 2 x 6 h, followed by SFM 2 x 6 hours; (4) water 4 x 6 h, followed by SFM 4 x 6
hours; and (5) water 2 x 12 h, followed by SFM 2 x 12 hours. Aliquots from these washing
steps (100 μL) were incubated with U87MG or HEK293A cells for 48 or 72 hours, after
which cell viability was measured using a a CellTiter-Glo® luminescent assay.

•

Biocompatibility assay of hydrogel components

U87MG glioblastoma cells were cultured in in DMEM medium supplemented with 10%
fetal bovine serum (FBS) and antibiotic-antimycotic solution (1×). All cells were grown in
5% CO2 incubators at 37 °C. Cell viability was measured post-treatment using a CellTiterGlo® luminescent viability assays following manufacturer instructions (Promega) on a
FLUOstar OPTIMA plate reader (BMG LABTECH). The biocompatibility assay was
performed by seeding U87MG cells in 96-well plates (4,000 cells/well). The cells were
then incubated for 48 hours with polyMPC (P5), MPC, PEGDMA, or VA-044 (0.1, 2.5, or
5 mg/mL). Cells alone served as a negative control.
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